ID   APOE_HUMAN              Reviewed;         317 AA.
AC   P02649; B2RC15; C0JYY5; Q9P2S4;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   02-OCT-2024, entry version 273.
DE   RecName: Full=Apolipoprotein E {ECO:0000305};
DE            Short=Apo-E;
DE   Flags: Precursor;
GN   Name=APOE {ECO:0000312|HGNC:HGNC:613};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE APOE*3).
RX   PubMed=6325438; DOI=10.1016/s0021-9258(18)91039-2;
RA   Zannis V.I., McPherson J., Goldberger G., Karathanasis S.K., Breslow J.L.;
RT   "Synthesis, intracellular processing, and signal peptide of human
RT   apolipoprotein E.";
RL   J. Biol. Chem. 259:5495-5499(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS THR-117 AND PRO-170.
RX   PubMed=6327682; DOI=10.1016/s0021-9258(20)82169-3;
RA   McLean J.W., Elshourbagy N.A., Chang D.J., Mahley R.W., Taylor J.M.;
RT   "Human apolipoprotein E mRNA. cDNA cloning and nucleotide sequencing of a
RT   new variant.";
RL   J. Biol. Chem. 259:6498-6504(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE APOE*4), AND VARIANT AD2 ARG-130.
RX   PubMed=2987927; DOI=10.1073/pnas.82.10.3445;
RA   Paik Y.-K., Chang D.J., Reardon C.A., Davies G.E., Mahley R.W.,
RA   Taylor J.M.;
RT   "Nucleotide sequence and structure of the human apolipoprotein E gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:3445-3449(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE APOE*2), AND VARIANT CYS-176.
RX   PubMed=3243553; DOI=10.1016/0888-7543(88)90130-9;
RA   Emi M., Wu L.L., Robertson M.A., Myers R.L., Hegele R.A., Williams R.R.,
RA   White R., Lalouel J.-M.;
RT   "Genotyping and sequence analysis of apolipoprotein E isoforms.";
RL   Genomics 3:373-379(1988).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE APOE*3).
RX   PubMed=10520737; DOI=10.3109/10425179809086433;
RA   Freitas E.M., Zhang W.J., Lalonde J.P., Tay G.K., Gaudieri S.,
RA   Ashworth L.K., Van Bockxmeer F.M., Dawkins R.L.;
RT   "Sequencing of 42kb of the APO E-C2 gene cluster reveals a new gene:
RT   PEREC1.";
RL   DNA Seq. 9:89-100(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE APOE*3), AND VARIANTS PRO-46;
RP   ARG-130; CYS-163 AND CYS-176.
RX   PubMed=11042151; DOI=10.1101/gr.146900;
RA   Nickerson D.A., Taylor S.L., Fullerton S.M., Weiss K.M., Clark A.G.,
RA   Stengard J.H., Salomaa V., Boerwinkle E., Sing C.F.;
RT   "Sequence diversity and large-scale typing of SNPs in the human
RT   apolipoprotein E gene.";
RL   Genome Res. 10:1532-1545(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE APOE*3).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE APOE*3).
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE APOE*3).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 16-78, AND VARIANT HIS-64.
RC   TISSUE=Blood;
RA   Imura T., Kimura H., Kawasaki M.;
RT   "A new apolipoprotein E variant (Gln46-->His).";
RL   Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 99-317 (ALLELE APOE*3).
RX   PubMed=6897404; DOI=10.1016/s0021-9258(18)33328-3;
RA   Breslow J.L., McPherson J., Nussbaum A.L., Williams H.W., Lofquist-Kahl F.,
RA   Karathanasis S.K., Zannis V.I.;
RT   "Identification and DNA sequence of a human apolipoprotein E cDNA clone.";
RL   J. Biol. Chem. 257:14639-14641(1982).
RN   [12]
RP   ERRATUM OF PUBMED:6897404.
RA   Breslow J.L., McPherson J., Nussbaum A.L., Williams H.W., Lofquist-Kahl F.,
RA   Karathanasis S.K., Zannis V.I.;
RL   J. Biol. Chem. 258:11422-11422(1983).
RN   [13]
RP   PROTEIN SEQUENCE OF 19-317 (ALLELE APOE*2).
RX   PubMed=7068630; DOI=10.1016/s0021-9258(18)34702-1;
RA   Rall S.C. Jr., Weisgraber K.H., Mahley R.W.;
RT   "Human apolipoprotein E. The complete amino acid sequence.";
RL   J. Biol. Chem. 257:4171-4178(1982).
RN   [14]
RP   FUNCTION IN LIPOPROTEINS CONVERSION.
RX   PubMed=6860692; DOI=10.1016/0005-2760(83)90047-4;
RA   Marcel Y.L., Vezina C., Milne R.W.;
RT   "Cholesteryl ester and apolipoprotein E transfer between human high density
RT   lipoproteins and chylomicrons.";
RL   Biochim. Biophys. Acta 750:411-417(1983).
RN   [15]
RP   HEPARIN-BINDING SITES.
RX   PubMed=3947350; DOI=10.1016/s0006-291x(86)80489-2;
RA   Cardin A.D., Hirose N., Blankenship D.T., Jackson R.L., Harmony J.A.K.,
RA   Sparrow D.A., Sparrow J.T.;
RT   "Binding of a high reactive heparin to human apolipoprotein E:
RT   identification of two heparin-binding domains.";
RL   Biochem. Biophys. Res. Commun. 134:783-789(1986).
RN   [16]
RP   TISSUE SPECIFICITY.
RX   PubMed=3115992; DOI=10.1016/s0021-9258(18)47945-8;
RA   Pitas R.E., Boyles J.K., Lee S.H., Hui D., Weisgraber K.H.;
RT   "Lipoproteins and their receptors in the central nervous system.
RT   Characterization of the lipoproteins in cerebrospinal fluid and
RT   identification of apolipoprotein B,E(LDL) receptors in the brain.";
RL   J. Biol. Chem. 262:14352-14360(1987).
RN   [17]
RP   INTERACTION WITH SORL1.
RX   PubMed=30448281; DOI=10.1016/j.cca.2018.11.024;
RA   Yano K., Hirayama S., Misawa N., Furuta A., Ueno T., Motoi Y., Seino U.,
RA   Ebinuma H., Ikeuchi T., Schneider W.J., Bujo H., Miida T.;
RT   "Soluble LR11 competes with amyloid beta in binding to cerebrospinal fluid-
RT   high-density lipoprotein.";
RL   Clin. Chim. Acta 489:29-34(2019).
RN   [18]
RP   CHARACTERIZATION OF VARIANTS SER-154 AND PRO-170, AND MUTAGENESIS OF
RP   SER-157; HIS-158; LYS-161; LEU-162; LEU-167 AND ARG-168.
RX   PubMed=2831187; DOI=10.1016/s0021-9258(18)68957-4;
RA   Lalazar A., Weisgraber K.H., Rall S.C. Jr., Giladi H., Innerarity T.L.,
RA   Levanon A.Z., Boyles J.K., Amit B., Gorecki M., Mahley R.W.;
RT   "Site-specific mutagenesis of human apolipoprotein E. Receptor binding
RT   activity of variants with single amino acid substitutions.";
RL   J. Biol. Chem. 263:3542-3545(1988).
RN   [19]
RP   SUBCELLULAR LOCATION, GLYCOSYLATION AT THR-212, AND MUTAGENESIS OF THR-212.
RX   PubMed=2498325; DOI=10.1016/s0021-9258(18)81907-x;
RA   Wernette-Hammond M.E., Lauer S.J., Corsini A., Walker D., Taylor J.M.,
RA   Rall S.C. Jr.;
RT   "Glycosylation of human apolipoprotein E. The carbohydrate attachment site
RT   is threonine 194.";
RL   J. Biol. Chem. 264:9094-9101(1989).
RN   [20]
RP   FUNCTION IN VLDL CLEARANCE.
RX   PubMed=2762297; DOI=10.1073/pnas.86.15.5810;
RA   Kowal R.C., Herz J., Goldstein J.L., Esser V., Brown M.S.;
RT   "Low density lipoprotein receptor-related protein mediates uptake of
RT   cholesteryl esters derived from apoprotein E-enriched lipoproteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:5810-5814(1989).
RN   [21]
RP   REGION, AND CHARACTERIZATION OF VARIANT ARG-130 AND ARG-176.
RX   PubMed=2280190;
RA   Weisgraber K.H.;
RT   "Apolipoprotein E distribution among human plasma lipoproteins: role of the
RT   cysteine-arginine interchange at residue 112.";
RL   J. Lipid Res. 31:1503-1511(1990).
RN   [22]
RP   FUNCTION IN CHYLOMICRONS CLEARANCE, AND SUBCELLULAR LOCATION.
RX   PubMed=1911868; DOI=10.1016/0005-2760(91)90138-8;
RA   Arnon R., Sehayek E., Vogel T., Eisenberg S.;
RT   "Effects of exogenous apo E-3 and of cholesterol-enriched meals on the
RT   cellular metabolism of human chylomicrons and their remnants.";
RL   Biochim. Biophys. Acta 1085:336-342(1991).
RN   [23]
RP   FUNCTION IN VLDL AND IDL CLEARANCE.
RX   PubMed=1917954; DOI=10.1016/s0021-9258(18)55263-7;
RA   Sehayek E., Eisenberg S.;
RT   "Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent
RT   cellular metabolism of human triglyceride-rich lipoproteins through the low
RT   density lipoprotein receptor pathway.";
RL   J. Biol. Chem. 266:18259-18267(1991).
RN   [24]
RP   SUBUNIT, SUBCELLULAR LOCATION, AND REGION.
RX   PubMed=8340399; DOI=10.1016/s0021-9258(18)82318-3;
RA   Westerlund J.A., Weisgraber K.H.;
RT   "Discrete carboxyl-terminal segments of apolipoprotein E mediate
RT   lipoprotein association and protein oligomerization.";
RL   J. Biol. Chem. 268:15745-15750(1993).
RN   [25]
RP   INTERACTION WITH APP/A4 AMYLOID-BETA PEPTIDE, AND CHARACTERIZATION OF
RP   VARIANT AD2 ARG-130.
RX   PubMed=8367470; DOI=10.1073/pnas.90.17.8098;
RA   Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvesen G.S.,
RA   Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D., Roses A.D.;
RT   "Binding of human apolipoprotein E to synthetic amyloid beta peptide:
RT   isoform-specific effects and implications for late-onset Alzheimer
RT   disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:8098-8102(1993).
RN   [26]
RP   INTERACTION WITH MAP2, AND CHARACTERIZATION OF VARIANT AD2 ARG-130.
RX   PubMed=7891887; DOI=10.1016/0304-3940(94)90204-6;
RA   Huang D.Y., Goedert M., Jakes R., Weisgraber K.H., Garner C.C.,
RA   Saunders A.M., Pericak-Vance M.A., Schmechel D.E., Roses A.D.,
RA   Strittmatter W.J.;
RT   "Isoform-specific interactions of apolipoprotein E with the microtubule-
RT   associated protein MAP2c: implications for Alzheimer's disease.";
RL   Neurosci. Lett. 182:55-58(1994).
RN   [27]
RP   INTERACTION WITH MAPT, AND CHARACTERIZATION OF VARIANT AD2 ARG-130.
RX   PubMed=7972031; DOI=10.1073/pnas.91.23.11183;
RA   Strittmatter W.J., Saunders A.M., Goedert M., Weisgraber K.H., Dong L.M.,
RA   Jakes R., Huang D.Y., Pericak-Vance M., Schmechel D., Roses A.D.;
RT   "Isoform-specific interactions of apolipoprotein E with microtubule-
RT   associated protein tau: implications for Alzheimer disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:11183-11186(1994).
RN   [28]
RP   FUNCTION, AND LRP2-BINDING.
RX   PubMed=7768901; DOI=10.1074/jbc.270.22.13070;
RA   Kounnas M.Z., Loukinova E.B., Stefansson S., Harmony J.A.K., Brewer B.H.,
RA   Strickland D.K., Argraves W.S.;
RT   "Identification of glycoprotein 330 as an endocytic receptor for
RT   apolipoprotein J/clusterin.";
RL   J. Biol. Chem. 270:13070-13075(1995).
RN   [29]
RP   FUNCTION IN NEURITE OUTGROWTH, LRP-BINDING, AND CHARACTERIZATION OF VARIANT
RP   AD2 ARG-130.
RX   PubMed=8939961; DOI=10.1074/jbc.271.47.30121;
RA   Fagan A.M., Bu G., Sun Y., Daugherty A., Holtzman D.M.;
RT   "Apolipoprotein E-containing high density lipoprotein promotes neurite
RT   outgrowth and is a ligand for the low density lipoprotein receptor-related
RT   protein.";
RL   J. Biol. Chem. 271:30121-30125(1996).
RN   [30]
RP   FUNCTION IN HDL CLEARANCE, AND HEPARAN SULFATE-BINDING.
RX   PubMed=9395455; DOI=10.1074/jbc.272.50.31285;
RA   Ji Z.S., Dichek H.L., Miranda R.D., Mahley R.W.;
RT   "Heparan sulfate proteoglycans participate in hepatic lipase and
RT   apolipoprotein E-mediated binding and uptake of plasma lipoproteins,
RT   including high density lipoproteins.";
RL   J. Biol. Chem. 272:31285-31292(1997).
RN   [31]
RP   FUNCTION, HEPARAN-SULFATE-BINDING, AND SUBCELLULAR LOCATION.
RX   PubMed=9488694; DOI=10.1074/jbc.273.10.5645;
RA   Burgess J.W., Gould D.R., Marcel Y.L.;
RT   "The HepG2 extracellular matrix contains separate heparinase- and lipid-
RT   releasable pools of ApoE. Implications for hepatic lipoprotein
RT   metabolism.";
RL   J. Biol. Chem. 273:5645-5654(1998).
RN   [32]
RP   TISSUE SPECIFICITY.
RX   PubMed=10027417; DOI=10.1016/s0002-9440(10)65305-9;
RA   Xu P.T., Gilbert J.R., Qiu H.L., Ervin J., Rothrock-Christian T.R.,
RA   Hulette C., Schmechel D.E.;
RT   "Specific regional transcription of apolipoprotein E in human brain
RT   neurons.";
RL   Am. J. Pathol. 154:601-611(1999).
RN   [33]
RP   GLYCATION AT LYS-93, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=10452964; DOI=10.1016/s0925-4439(99)00047-2;
RA   Shuvaev V.V., Fujii J., Kawasaki Y., Itoh H., Hamaoka R., Barbier A.,
RA   Ziegler O., Siest G., Taniguchi N.;
RT   "Glycation of apolipoprotein E impairs its binding to heparin:
RT   identification of the major glycation site.";
RL   Biochim. Biophys. Acta 1454:296-308(1999).
RN   [34]
RP   PTM, AND CHARACTERIZATION OF VARIANT AD2 ARG-130.
RX   PubMed=11447277; DOI=10.1073/pnas.151254698;
RA   Huang Y., Liu X.Q., Wyss-Coray T., Brecht W.J., Sanan D.A., Mahley R.W.;
RT   "Apolipoprotein E fragments present in Alzheimer's disease brains induce
RT   neurofibrillary tangle-like intracellular inclusions in neurons.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8838-8843(2001).
RN   [35]
RP   FUNCTION, LRP8-BINDING, AND CHARACTERIZATION OF VARIANT CYS-176.
RX   PubMed=12950167; DOI=10.1021/bi027093c;
RA   Li X., Kypreos K., Zanni E.E., Zannis V.;
RT   "Domains of apoE required for binding to apoE receptor 2 and to
RT   phospholipids: implications for the functions of apoE in the brain.";
RL   Biochemistry 42:10406-10417(2003).
RN   [36]
RP   FUNCTION IN REVERSE CHOLESTEROL TRANSPORT, AND INTERACTION WITH ABCA1.
RX   PubMed=14754908; DOI=10.1194/jlr.m300418-jlr200;
RA   Krimbou L., Denis M., Haidar B., Carrier M., Marcil M., Genest J. Jr.;
RT   "Molecular interactions between apoE and ABCA1: impact on apoE
RT   lipidation.";
RL   J. Lipid Res. 45:839-848(2004).
RN   [37]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT THR-212; THR-307 AND SER-308, AND
RP   STRUCTURE OF CARBOHYDRATES.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=19838169; DOI=10.1038/nmeth.1392;
RA   Nilsson J., Rueetschi U., Halim A., Hesse C., Carlsohn E., Brinkmalm G.,
RA   Larson G.;
RT   "Enrichment of glycopeptides for glycan structure and attachment site
RT   identification.";
RL   Nat. Methods 6:809-811(2009).
RN   [38]
RP   FUNCTION, LRP1-BINDING, AND REGION.
RX   PubMed=20030366; DOI=10.1021/bi9017208;
RA   Guttman M., Prieto J.H., Croy J.E., Komives E.A.;
RT   "Decoding of lipoprotein-receptor interactions: properties of ligand
RT   binding modules governing interactions with apolipoprotein E.";
RL   Biochemistry 49:1207-1216(2010).
RN   [39]
RP   GLYCOSYLATION AT SER-308.
RX   PubMed=20511397; DOI=10.1074/mcp.m900430-mcp200;
RA   Lee Y., Kockx M., Raftery M.J., Jessup W., Griffith R., Kritharides L.;
RT   "Glycosylation and sialylation of macrophage-derived human apolipoprotein E
RT   analyzed by SDS-PAGE and mass spectrometry: evidence for a novel site of
RT   glycosylation on Ser290.";
RL   Mol. Cell. Proteomics 9:1968-1981(2010).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [41]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S., Fischer-Posovszky P.,
RA   Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [42]
RP   FUNCTION IN LIPOPROTEIN CLEARANCE, AND HEPARAN-SULFATE PROTEOGLYCANS
RP   BINDING.
RX   PubMed=23676495; DOI=10.1172/jci67398;
RA   Gonzales J.C., Gordts P.L., Foley E.M., Esko J.D.;
RT   "Apolipoproteins E and AV mediate lipoprotein clearance by hepatic
RT   proteoglycans.";
RL   J. Clin. Invest. 123:2742-2751(2013).
RN   [43]
RP   GLYCOSYLATION AT THR-26; THR-36 AND SER-314, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=23234360; DOI=10.1021/pr300963h;
RA   Halim A., Ruetschi U., Larson G., Nilsson J.;
RT   "LC-MS/MS characterization of O-glycosylation sites and glycan structures
RT   of human cerebrospinal fluid glycoproteins.";
RL   J. Proteome Res. 12:573-584(2013).
RN   [44]
RP   FUNCTION IN CHOLESTEROL EFFLUX, AND INTERACTION WITH APP/A4 AMYLOID-BETA
RP   PEPTIDE.
RX   PubMed=23620513; DOI=10.1073/pnas.1220484110;
RA   Verghese P.B., Castellano J.M., Garai K., Wang Y., Jiang H., Shah A.,
RA   Bu G., Frieden C., Holtzman D.M.;
RT   "ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta
RT   association in physiological conditions.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:E1807-E1816(2013).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-147, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [46]
RP   INTERACTION WITH HCV ENVELOPE GLYCOPROTEIN E2 (MICROBIAL INFECTION), AND
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=25122793; DOI=10.1128/jvi.01660-14;
RA   Lee J.Y., Acosta E.G., Stoeck I.K., Long G., Hiet M.S., Mueller B.,
RA   Fackler O.T., Kallis S., Bartenschlager R.;
RT   "Apolipoprotein E likely contributes to a maturation step of infectious
RT   hepatitis C virus particles and interacts with viral envelope
RT   glycoproteins.";
RL   J. Virol. 88:12422-12437(2014).
RN   [47]
RP   PHOSPHORYLATION AT SER-147.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [48]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PMEL.
RX   PubMed=26387950; DOI=10.1016/j.celrep.2015.08.057;
RA   van Niel G., Bergam P., Di Cicco A., Hurbain I., Lo Cicero A., Dingli F.,
RA   Palmulli R., Fort C., Potier M.C., Schurgers L.J., Loew D., Levy D.,
RA   Raposo G.;
RT   "Apolipoprotein E Regulates Amyloid Formation within Endosomes of Pigment
RT   Cells.";
RL   Cell Rep. 13:43-51(2015).
RN   [49]
RP   FUNCTION IN APP TRANSCRIPTION, AND CHARACTERIZATION OF VARIANT AD2 ARG-130.
RX   PubMed=28111074; DOI=10.1016/j.cell.2016.12.044;
RA   Huang Y.A., Zhou B., Wernig M., Suedhof T.C.;
RT   "ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and
RT   Abeta Secretion.";
RL   Cell 168:427-441(2017).
RN   [50]
RP   INTERACTION WITH HCV ENVELOPE GLYCOPROTEIN E2 (MICROBIAL INFECTION), AND
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=29695434; DOI=10.1128/jvi.00211-18;
RA   Kim J.Y., Ou J.J.;
RT   "Regulation of Apolipoprotein E Trafficking by Hepatitis C Virus-Induced
RT   Autophagy.";
RL   J. Virol. 92:e00211-e00218(2018).
RN   [51]
RP   FUNCTION, SUBCELLULAR LOCATION, AND ROLE IN TUMOR CELL INFILTRATION.
RX   PubMed=30333625; DOI=10.1038/s41586-018-0615-z;
RA   Deng M., Gui X., Kim J., Xie L., Chen W., Li Z., He L., Chen Y., Chen H.,
RA   Luo W., Lu Z., Xie J., Churchill H., Xu Y., Zhou Z., Wu G., Yu C., John S.,
RA   Hirayasu K., Nguyen N., Liu X., Huang F., Li L., Deng H., Tang H.,
RA   Sadek A.H., Zhang L., Huang T., Zou Y., Chen B., Zhu H., Arase H., Xia N.,
RA   Jiang Y., Collins R., You M.J., Homsi J., Unni N., Lewis C., Chen G.Q.,
RA   Fu Y.X., Liao X.C., An Z., Zheng J., Zhang N., Zhang C.C.;
RT   "LILRB4 signalling in leukaemia cells mediates T cell suppression and
RT   tumour infiltration.";
RL   Nature 562:605-609(2018).
RN   [52] {ECO:0007744|PDB:1LPE}
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 41-184, FUNCTION, AND REGION.
RX   PubMed=2063194; DOI=10.1126/science.2063194;
RA   Wilson C., Wardell M.R., Weisgraber K.H., Mahley R.W., Agard D.A.;
RT   "Three-dimensional structure of the LDL receptor-binding domain of human
RT   apolipoprotein E.";
RL   Science 252:1817-1822(1991).
RN   [53] {ECO:0007744|PDB:1LE4}
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 41-184 OF VARIANT AD2 ARG-130,
RP   CHARACTERIZATION OF VARIANT AD2 ARG-130, MUTAGENESIS OF ARG-79 AND GLU-127,
RP   AND REGION.
RX   PubMed=8071364; DOI=10.1016/s0021-9258(17)31797-0;
RA   Dong L.M., Wilson C., Wardell M.R., Simmons T., Mahley R.W.,
RA   Weisgraber K.H., Agard D.A.;
RT   "Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein
RT   preferences of the E3 and E4 isoforms.";
RL   J. Biol. Chem. 269:22358-22365(1994).
RN   [54] {ECO:0007744|PDB:1LE2}
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 41-184 OF VARIANT CYS-176, AND
RP   CHARACTERIZATION OF VARIANT CYS-176.
RX   PubMed=7994571; DOI=10.1016/s0969-2126(00)00072-1;
RA   Wilson C., Mau T., Weisgraber K.H., Wardell M.R., Mahley R.W., Agard D.A.;
RT   "Salt bridge relay triggers defective LDL receptor binding by a mutant
RT   apolipoprotein.";
RL   Structure 2:713-718(1994).
RN   [55] {ECO:0007744|PDB:1NFN, ECO:0007744|PDB:1NFO}
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 19-209 OF VARIANT CYS-176,
RP   MUTAGENESIS OF ASP-172, CHARACTERIZATION OF VARIANT CYS-176, FUNCTION, AND
RP   LDLR-BINDING.
RX   PubMed=8756331; DOI=10.1038/nsb0896-718;
RA   Dong L.-M., Parkin S., Trakhanov S.D., Rupp B., Simmons T., Arnold K.S.,
RA   Newhouse Y.M., Innerarity T.L., Weisgraber K.H.;
RT   "Novel mechanism for defective receptor binding of apolipoprotein E2 in
RT   type III hyperlipoproteinemia.";
RL   Nat. Struct. Biol. 3:718-722(1996).
RN   [56] {ECO:0007744|PDB:1BZ4, ECO:0007744|PDB:1OR2, ECO:0007744|PDB:1OR3}
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 19-183.
RX   PubMed=10850798; DOI=10.1110/ps.9.5.886;
RA   Segelke B.W., Forstner M., Knapp M., Trakhanov S.D., Parkin S.,
RA   Newhouse Y.M., Bellamy H.D., Weisgraber K.H., Rupp B.;
RT   "Conformational flexibility in the apolipoprotein E amino-terminal domain
RT   structure determined from three new crystal forms: implications for lipid
RT   binding.";
RL   Protein Sci. 9:886-897(2000).
RN   [57] {ECO:0007744|PDB:1B68}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 19-209 OF VARIANT AD2 ARG-130.
RX   PubMed=11258893; DOI=10.1021/bi002417n;
RA   Dong J., Peters-Libeu C.A., Weisgraber K.H., Segelke B.W., Rupp B.,
RA   Capila I., Hernaiz M.J., LeBrun L.A., Linhardt R.J.;
RT   "Interaction of the N-terminal domain of apolipoprotein E4 with heparin.";
RL   Biochemistry 40:2826-2834(2001).
RN   [58] {ECO:0007744|PDB:2KNY}
RP   STRUCTURE BY NMR OF 147-167 IN COMPLEX WITH LRP1, FUNCTION, AND
RP   LRP1-BINDING.
RX   PubMed=20303980; DOI=10.1016/j.jmb.2010.03.022;
RA   Guttman M., Prieto J.H., Handel T.M., Domaille P.J., Komives E.A.;
RT   "Structure of the minimal interface between ApoE and LRP.";
RL   J. Mol. Biol. 398:306-319(2010).
RN   [59]
RP   VARIANT HLPP3 262-GLU-GLU-263 DELINS LYS-LYS.
RX   PubMed=2738044; DOI=10.1093/oxfordjournals.jbchem.a122618;
RA   Maeda H., Nakamura H., Kobori S., Okada M., Mori H., Niki H., Ogura T.,
RA   Hiraga S.;
RT   "Identification of human apolipoprotein E variant gene: apolipoprotein E7
RT   (Glu244,245----Lys244,245).";
RL   J. Biochem. 105:51-54(1989).
RN   [60]
RP   VARIANT LYS-21.
RX   PubMed=2760009; DOI=10.1093/oxfordjournals.jbchem.a122692;
RA   Maeda H., Nakamura H., Kobori S., Okada M., Niki H., Ogura T., Hiraga S.;
RT   "Molecular cloning of a human apolipoprotein E variant: E5 (Glu-3-->Lys).";
RL   J. Biochem. 105:491-493(1989).
RN   [61]
RP   VARIANTS HLPP3 ARG-130 AND GLU-VAL-GLN-ALA-MET-LEU-GLY-145 INS.
RX   PubMed=2556398; DOI=10.1016/s0021-9258(19)30067-5;
RA   Wardell M.R., Weisgraber K.H., Havekes L.M., Rall S.C. Jr.;
RT   "Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a
RT   tandem repeat of residues 121-127.";
RL   J. Biol. Chem. 264:21205-21210(1989).
RN   [62]
RP   VARIANT HLPP3 HIS-163.
RX   PubMed=2101409; DOI=10.2169/internalmedicine1962.29.587;
RA   Suehiro T., Yoshida K., Yamano T., Ohno F.;
RT   "Identification and characterization of a new variant of apolipoprotein E
RT   (apo E-Kochi).";
RL   Jpn. J. Med. 29:587-594(1990).
RN   [63]
RP   VARIANT CYS-246.
RX   PubMed=2341812;
RA   Wardell M.R., Rall S.C. Jr., Brennan S.O., Nye E.R., George P.M.,
RA   Janus E.D., Weisgraber K.H.;
RT   "Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2
RT   variant with normal receptor-binding activity.";
RL   J. Lipid Res. 31:535-543(1990).
RN   [64]
RP   VARIANTS HLPP3 LYS-31 AND CYS-163.
RX   PubMed=1674745; DOI=10.1016/s0021-9258(18)99249-5;
RA   Lohse P., Mann W.A., Stein E.A., Brewer H.B. Jr.;
RT   "Apolipoprotein E-4 Philadelphia (Glu-13-->Lys,Arg-145-->Cys). Homozygosity
RT   for two rare point mutations in the apolipoprotein E gene combined with
RT   severe type III hyperlipoproteinemia.";
RL   J. Biol. Chem. 266:10479-10484(1991).
RN   [65]
RP   VARIANT APOE5 FRENCH-CANADIAN LYS-31.
RX   PubMed=1713245;
RA   Mailly F., Xu C.F., Xhignesse M., Lussier-Cacan S., Talmud P.J.,
RA   Davignon J., Humphries S.E., Nestruck A.C.;
RT   "Characterization of a new apolipoprotein E5 variant detected in two
RT   French-Canadian subjects.";
RL   J. Lipid Res. 32:613-620(1991).
RN   [66]
RP   CHARACTERIZATION OF VARIANT LYS-21, FUNCTION, AND LDLR-BINDING.
RX   PubMed=1530612; DOI=10.1016/0006-291x(92)91321-g;
RA   Dong L.M., Yamamura T., Tajima S., Yamamoto A.;
RT   "Site-directed mutagenesis of an apolipoprotein E mutant, apo E5(Glu3----
RT   Lys) and its binding to low density lipoprotein receptors.";
RL   Biochem. Biophys. Res. Commun. 187:1180-1186(1992).
RN   [67]
RP   VARIANT HLPP3 228-TRP--HIS-317 DEL.
RX   PubMed=1361196;
RA   Lohse P., Brewer H.B. III, Meng M.S., Skarlatos S.I., LaRosa J.C.,
RA   Brewer H.B. Jr.;
RT   "Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due
RT   to a premature stop codon in the apolipoprotein E gene.";
RL   J. Lipid Res. 33:1583-1590(1992).
RN   [68]
RP   VARIANTS GLU-254; GLY-269; GLU-270; HIS-292 AND ARG-314.
RX   PubMed=8488843;
RA   van den Maagdenberg A.M.J.M., Weng W., de Bruijn I.H., de Knijff P.,
RA   Funke H., Smelt A.H.M., Leuven J.A.G., van 't Hooft F.M., Assmann G.,
RA   Hofker M.H., Havekes L.M., Frants R.R.;
RT   "Characterization of five new mutants in the carboxyl-terminal domain of
RT   human apolipoprotein E: no cosegregation with severe hyperlipidemia.";
RL   Am. J. Hum. Genet. 52:937-946(1993).
RN   [69]
RP   VARIANTS LYS-99 AND ARG-130.
RX   PubMed=8125051; DOI=10.1002/elps.11501401164;
RA   Ruzicka V., Maerz W., Russ A., Fisher E., Mondorf W., Gross W.;
RT   "Characterization of the gene for apolipoprotein E5-Frankfurt (Gln81->Lys,
RT   Cys112->Arg) by polymerase chain reaction, restriction isotyping, and
RT   temperature gradient gel electrophoresis.";
RL   Electrophoresis 14:1032-1037(1993).
RN   [70]
RP   CHARACTERIZATION OF VARIANT GLU-VAL-GLN-ALA-MET-LEU-GLY-145 INS.
RX   PubMed=8468528;
RA   Fazio S., Horie Y., Weisgraber K.H., Havekes L.M., Rall S.C. Jr.;
RT   "Preferential association of apolipoprotein E Leiden with very low density
RT   lipoproteins of human plasma.";
RL   J. Lipid Res. 34:447-453(1993).
RN   [71]
RP   INVOLVEMENT IN AD2, AND VARIANT AD2 ARG-130.
RX   PubMed=8346443; DOI=10.1126/science.8346443;
RA   Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E.,
RA   Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A.;
RT   "Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's
RT   disease in late onset families.";
RL   Science 261:921-923(1993).
RN   [72]
RP   VARIANTS HLPP3 ARG-130; SER-154; CYS-160 AND CYS-176, AND VARIANT ASP-145.
RX   PubMed=8287539;
RA   Richard P., Thomas G., de Zulueta M.P., de Gennes J.-L., Thomas M.,
RA   Cassaigne A., Bereziat G., Iron A.;
RT   "Common and rare genotypes of human apolipoprotein E determined by specific
RT   restriction profiles of polymerase chain reaction-amplified DNA.";
RL   Clin. Chem. 40:24-29(1994).
RN   [73]
RP   VARIANT HLPP3 GLU-164, CHARACTERIZATION OF VARIANT HLPP3 GLU-164 AND
RP   CYS-176, FUNCTION, LDLR-BINDING, AND HEPARIN-BINDING.
RX   PubMed=7635945; DOI=10.1172/jci118096;
RA   Mann W.A., Lohse P., Gregg R.E., Ronan R., Hoeg J.M., Zech L.A.,
RA   Brewer H.B. Jr.;
RT   "Dominant expression of type III hyperlipoproteinemia. Pathophysiological
RT   insights derived from the structural and kinetic characteristics of ApoE-1
RT   (Lys146-->Glu).";
RL   J. Clin. Invest. 96:1100-1107(1995).
RN   [74]
RP   VARIANT GLN-242.
RX   PubMed=8664327; DOI=10.1016/0005-2760(96)00014-8;
RA   Moriyama K., Sasaki J., Takada Y., Arakawa F., Matsunaga A., Ito Y.,
RA   Arakawa K.;
RT   "Characterization of a novel variant of apolipoprotein E, E2 Fukuoka (Arg-
RT   224 --> Gln) in a hyperlipidemic patient with xanthomatosis.";
RL   Biochim. Biophys. Acta 1301:185-190(1996).
RN   [75]
RP   VARIANT LPG PRO-163.
RX   PubMed=9176854; DOI=10.1681/asn.v85820;
RA   Oikawa S., Matsunaga A., Saito T., Sato H., Seki T., Hoshi K., Hayasaka K.,
RA   Kotake H., Midorikawa H., Sekikawa A., Hara S., Abe K., Toyota T.,
RA   Jingami H., Nakamura H., Sasaki J.;
RT   "Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated
RT   with lipoprotein glomerulopathy.";
RL   J. Am. Soc. Nephrol. 8:820-823(1997).
RN   [76]
RP   VARIANTS ARG-130 AND GLY-269.
RX   PubMed=9360638; DOI=10.1016/s1383-5726(97)00009-5;
RA   Kang A.K., Jenkins D.J.A., Wolever T.M.S., Huff M.W., Maguire G.F.,
RA   Connelly P.W., Hegele R.A.;
RT   "Apolipoprotein E R112; R251G: a carboxy-terminal variant found in patients
RT   with hyperlipidemia and coronary heart disease.";
RL   Mutat. Res. 382:57-65(1997).
RN   [77]
RP   VARIANT LPG CYS-43.
RX   PubMed=10432380; DOI=10.1046/j.1523-1755.1999.00572.x;
RA   Matsunaga A., Sasaki J., Komatsu T., Kanatsu K., Tsuji E., Moriyama K.,
RA   Koga T., Arakawa K., Oikawa S., Saito T., Kita T., Doi T.;
RT   "A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein
RT   glomerulopathy.";
RL   Kidney Int. 56:421-427(1999).
RN   [78]
RP   CHARACTERIZATION OF VARIANT LPG PRO-163, AND CHARACTERIZATION OF VARIANT
RP   AD2 ARG-130.
RX   PubMed=10903326; DOI=10.1074/jbc.m005906200;
RA   Ishigaki Y., Oikawa S., Suzuki T., Usui S., Magoori K., Kim D.H.,
RA   Suzuki H., Sasaki J., Sasano H., Okazaki M., Toyota T., Saito T.,
RA   Yamamoto T.T.;
RT   "Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops
RT   lipoprotein glomerulopathy in ApoE-deficient mice.";
RL   J. Biol. Chem. 275:31269-31273(2000).
RN   [79]
RP   VARIANT SBHD LEU-167 DEL.
RX   PubMed=11095479; DOI=10.1210/jcem.85.11.6981;
RA   Nguyen T.T., Kruckeberg K.E., O'Brien J.F., Ji Z.-S., Karnes P.S.,
RA   Crotty T.B., Hay I.D., Mahley R.W., O'Brien T.;
RT   "Familial splenomegaly: macrophage hypercatabolism of lipoproteins
RT   associated with apolipoprotein E mutation [apolipoprotein E (delta149
RT   Leu)].";
RL   J. Clin. Endocrinol. Metab. 85:4354-4358(2000).
RN   [80]
RP   VARIANT VAL-124.
RX   PubMed=12864777; DOI=10.1046/j.1365-2362.2003.01180.x;
RA   Miserez A.R., Scharnagl H., Muller P.Y., Mirsaidi R., Stahelin H.B.,
RA   Monsch A., Marz W., Hoffmann M.M.;
RT   "Apolipoprotein E3Basel: new insights into a highly conserved protein
RT   region.";
RL   Eur. J. Clin. Invest. 33:677-685(2003).
RN   [81]
RP   VARIANTS ARG-130 AND CYS-176.
RX   PubMed=12966036; DOI=10.1093/hmg/ddg314;
RA   Morabia A., Cayanis E., Costanza M.C., Ross B.M., Flaherty M.S.,
RA   Alvin G.B., Das K., Gilliam T.C.;
RT   "Association of extreme blood lipid profile phenotypic variation with 11
RT   reverse cholesterol transport genes and 10 non-genetic cardiovascular
RT   disease risk factors.";
RL   Hum. Mol. Genet. 12:2733-2743(2003).
RN   [82]
RP   VARIANT SBHD LEU-167 DEL.
RX   PubMed=16094309; DOI=10.1038/sj.ejhg.5201480;
RA   Faivre L., Saugier-Veber P., Pais de Barros J.-P., Verges B., Couret B.,
RA   Lorcerie B., Thauvin C., Charbonnier F., Huet F., Gambert P., Frebourg T.,
RA   Duvillard L.;
RT   "Variable expressivity of the clinical and biochemical phenotype associated
RT   with the apolipoprotein E p.Leu149del mutation.";
RL   Eur. J. Hum. Genet. 13:1186-1191(2005).
RN   [83]
RP   VARIANT LPG CYS-43.
RX   PubMed=18077821; DOI=10.1056/nejmc072088;
RA   Rovin B.H., Roncone D., McKinley A., Nadasdy T., Korbet S.M.,
RA   Schwartz M.M.;
RT   "APOE Kyoto mutation in European Americans with lipoprotein
RT   glomerulopathy.";
RL   N. Engl. J. Med. 357:2522-2524(2007).
RN   [84]
RP   VARIANT HIS-64, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22028381; DOI=10.1093/jmcb/mjr024;
RA   Su Z.D., Sun L., Yu D.X., Li R.X., Li H.X., Yu Z.J., Sheng Q.H., Lin X.,
RA   Zeng R., Wu J.R.;
RT   "Quantitative detection of single amino acid polymorphisms by targeted
RT   proteomics.";
RL   J. Mol. Cell Biol. 3:309-315(2011).
RN   [85]
RP   VARIANT HLPP3 SER-154, AND VARIANT SBHD LEU-167 DEL.
RX   PubMed=22481068; DOI=10.1016/j.atherosclerosis.2012.03.011;
RA   Solanas-Barca M., de Castro-Oros I., Mateo-Gallego R., Cofan M., Plana N.,
RA   Puzo J., Burillo E., Martin-Fuentes P., Ros E., Masana L., Pocovi M.,
RA   Civeira F., Cenarro A.;
RT   "Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and
RT   a clinical diagnosis of familial combined hyperlipidemia.";
RL   Atherosclerosis 222:449-455(2012).
RN   [86]
RP   VARIANT SBHD LEU-167 DEL.
RX   PubMed=24267230; DOI=10.1016/j.atherosclerosis.2013.09.007;
RA   Awan Z., Choi H.Y., Stitziel N., Ruel I., Bamimore M.A., Husa R.,
RA   Gagnon M.H., Wang R.H., Peloso G.M., Hegele R.A., Seidah N.G.,
RA   Kathiresan S., Genest J.;
RT   "APOE p.Leu167del mutation in familial hypercholesterolemia.";
RL   Atherosclerosis 231:218-222(2013).
RN   [87]
RP   VARIANT SBHD LEU-167 DEL.
RX   PubMed=22949395; DOI=10.1002/humu.22215;
RA   Marduel M., Ouguerram K., Serre V., Bonnefont-Rousselot D.,
RA   Marques-Pinheiro A., Erik Berge K., Devillers M., Luc G., Lecerf J.M.,
RA   Tosolini L., Erlich D., Peloso G.M., Stitziel N., Nitchke P., Jais J.P.,
RA   Abifadel M., Kathiresan S., Leren T.P., Rabes J.P., Boileau C., Varret M.;
RT   "Description of a large family with autosomal dominant hypercholesterolemia
RT   associated with the APOE p.Leu167del mutation.";
RL   Hum. Mutat. 34:83-87(2013).
RN   [88]
RP   VARIANTS PRO-46 AND ASP-145, VARIANT HLPP3 CYS-163, AND VARIANT SBHD
RP   LEU-167 DEL.
RX   PubMed=26802169; DOI=10.1194/jlr.p055699;
RA   Wintjens R., Bozon D., Belabbas K., Mbou F., Girardet J.P., Tounian P.,
RA   Jolly M., Boccara F., Cohen A., Karsenty A., Dubern B., Carel J.C.,
RA   Azar-Kolakez A., Feillet F., Labarthe F., Gorsky A.M., Horovitz A.,
RA   Tamarindi C., Kieffer P., Lienhardt A., Lascols O., Di Filippo M.,
RA   Dufernez F.;
RT   "Global molecular analysis and APOE mutations in a cohort of autosomal
RT   dominant hypercholesterolemia patients in France.";
RL   J. Lipid Res. 57:482-491(2016).
RN   [89]
RP   REVIEW, AND VARIANTS LYS-31; ARG-102; ARG-130; GLN-152 AND CYS-154.
RX   PubMed=7833947; DOI=10.1002/humu.1380040303;
RA   de Knijff P., van den Maagdenberg A.M.J.M., Frants R.R., Havekes L.M.;
RT   "Genetic heterogeneity of apolipoprotein E and its influence on plasma
RT   lipid and lipoprotein levels.";
RL   Hum. Mutat. 4:178-194(1994).
RN   [90]
RP   REVIEW, POLYMORPHISM, AND TISSUE SPECIFICITY.
RX   PubMed=25173806; DOI=10.1016/j.nbd.2014.08.025;
RA   Huang Y., Mahley R.W.;
RT   "Apolipoprotein E: structure and function in lipid metabolism,
RT   neurobiology, and Alzheimer's diseases.";
RL   Neurobiol. Dis. 72:3-12(2014).
RN   [91]
RP   REVIEW, FUNCTION, AND PTM.
RX   PubMed=29516132; DOI=10.1007/s00109-018-1632-y;
RA   Kockx M., Traini M., Kritharides L.;
RT   "Cell-specific production, secretion, and function of apolipoprotein E.";
RL   J. Mol. Med. 96:361-371(2018).
RN   [92]
RP   POLYMORPHISM, AND VARIANT ARG-130.
RX   PubMed=33450186; DOI=10.1016/j.stem.2020.12.018;
RA   Wang C., Zhang M., Garcia G. Jr., Tian E., Cui Q., Chen X., Sun G.,
RA   Wang J., Arumugaswami V., Shi Y.;
RT   "ApoE-Isoform-Dependent SARS-CoV-2 Neurotropism and Cellular Response.";
RL   Cell Stem Cell 0:0-0(2021).
CC   -!- FUNCTION: APOE is an apolipoprotein, a protein associating with lipid
CC       particles, that mainly functions in lipoprotein-mediated lipid
CC       transport between organs via the plasma and interstitial fluids
CC       (PubMed:14754908, PubMed:1911868, PubMed:6860692). APOE is a core
CC       component of plasma lipoproteins and is involved in their production,
CC       conversion and clearance (PubMed:14754908, PubMed:1911868,
CC       PubMed:1917954, PubMed:23620513, PubMed:2762297, PubMed:6860692,
CC       PubMed:9395455). Apolipoproteins are amphipathic molecules that
CC       interact both with lipids of the lipoprotein particle core and the
CC       aqueous environment of the plasma (PubMed:2762297, PubMed:6860692,
CC       PubMed:9395455). As such, APOE associates with chylomicrons,
CC       chylomicron remnants, very low density lipoproteins (VLDL) and
CC       intermediate density lipoproteins (IDL) but shows a preferential
CC       binding to high-density lipoproteins (HDL) (PubMed:1911868,
CC       PubMed:6860692). It also binds a wide range of cellular receptors
CC       including the LDL receptor/LDLR, the LDL receptor-related proteins
CC       LRP1, LRP2 and LRP8 and the very low-density lipoprotein receptor/VLDLR
CC       that mediate the cellular uptake of the APOE-containing lipoprotein
CC       particles (PubMed:12950167, PubMed:1530612, PubMed:1917954,
CC       PubMed:20030366, PubMed:20303980, PubMed:2063194, PubMed:2762297,
CC       PubMed:7635945, PubMed:7768901, PubMed:8756331, PubMed:8939961).
CC       Finally, APOE has also a heparin-binding activity and binds heparan-
CC       sulfate proteoglycans on the surface of cells, a property that supports
CC       the capture and the receptor-mediated uptake of APOE-containing
CC       lipoproteins by cells (PubMed:23676495, PubMed:7635945, PubMed:9395455,
CC       PubMed:9488694). A main function of APOE is to mediate lipoprotein
CC       clearance through the uptake of chylomicrons, VLDLs, and HDLs by
CC       hepatocytes (PubMed:1911868, PubMed:1917954, PubMed:23676495,
CC       PubMed:29516132, PubMed:9395455). APOE is also involved in the
CC       biosynthesis by the liver of VLDLs as well as their uptake by
CC       peripheral tissues ensuring the delivery of triglycerides and energy
CC       storage in muscle, heart and adipose tissues (PubMed:2762297,
CC       PubMed:29516132). By participating in the lipoprotein-mediated
CC       distribution of lipids among tissues, APOE plays a critical role in
CC       plasma and tissues lipid homeostasis (PubMed:1917954, PubMed:2762297,
CC       PubMed:29516132). APOE is also involved in two steps of reverse
CC       cholesterol transport, the HDLs-mediated transport of cholesterol from
CC       peripheral tissues to the liver, and thereby plays an important role in
CC       cholesterol homeostasis (PubMed:14754908, PubMed:23620513,
CC       PubMed:9395455). First, it is functionally associated with ABCA1 in the
CC       biogenesis of HDLs in tissues (PubMed:14754908, PubMed:23620513).
CC       Second, it is enriched in circulating HDLs and mediates their uptake by
CC       hepatocytes (PubMed:9395455). APOE also plays an important role in
CC       lipid transport in the central nervous system, regulating neuron
CC       survival and sprouting (PubMed:25173806, PubMed:8939961). APOE is also
CC       involved in innate and adaptive immune responses, controlling for
CC       instance the survival of myeloid-derived suppressor cells (By
CC       similarity). Binds to the immune cell receptor LILRB4
CC       (PubMed:30333625). APOE may also play a role in transcription
CC       regulation through a receptor-dependent and cholesterol-independent
CC       mechanism, that activates MAP3K12 and a non-canonical MAPK signal
CC       transduction pathway that results in enhanced AP-1-mediated
CC       transcription of APP (PubMed:28111074). {ECO:0000250|UniProtKB:P08226,
CC       ECO:0000269|PubMed:12950167, ECO:0000269|PubMed:14754908,
CC       ECO:0000269|PubMed:1530612, ECO:0000269|PubMed:1911868,
CC       ECO:0000269|PubMed:1917954, ECO:0000269|PubMed:20030366,
CC       ECO:0000269|PubMed:20303980, ECO:0000269|PubMed:2063194,
CC       ECO:0000269|PubMed:23620513, ECO:0000269|PubMed:23676495,
CC       ECO:0000269|PubMed:2762297, ECO:0000269|PubMed:28111074,
CC       ECO:0000269|PubMed:30333625, ECO:0000269|PubMed:6860692,
CC       ECO:0000269|PubMed:7635945, ECO:0000269|PubMed:7768901,
CC       ECO:0000269|PubMed:8756331, ECO:0000269|PubMed:8939961,
CC       ECO:0000269|PubMed:9395455, ECO:0000269|PubMed:9488694,
CC       ECO:0000303|PubMed:25173806, ECO:0000303|PubMed:29516132}.
CC   -!- FUNCTION: (Microbial infection) Through its interaction with HCV
CC       envelope glycoprotein E2, participates in the attachment of HCV to
CC       HSPGs and other receptors (LDLr, VLDLr, and SR-B1) on the cell surface
CC       and to the assembly, maturation and infectivity of HCV viral particles
CC       (PubMed:25122793, PubMed:29695434). This interaction is probably
CC       promoted via the up-regulation of cellular autophagy by the virus
CC       (PubMed:29695434). {ECO:0000269|PubMed:25122793,
CC       ECO:0000269|PubMed:29695434}.
CC   -!- SUBUNIT: Homotetramer (PubMed:8340399). May interact with ABCA1;
CC       functionally associated with ABCA1 in the biogenesis of HDLs
CC       (PubMed:14754908). May interact with APP/A4 amyloid-beta peptide; the
CC       interaction is extremely stable in vitro but its physiological
CC       significance is unclear (PubMed:23620513, PubMed:8367470). May interact
CC       with MAPT (PubMed:7972031). May interact with MAP2 (PubMed:7891887). In
CC       the cerebrospinal fluid, interacts with secreted SORL1
CC       (PubMed:30448281). Interacts with PMEL; this allows the loading of PMEL
CC       luminal fragment on ILVs to induce fibril nucleation.
CC       {ECO:0000269|PubMed:14754908, ECO:0000269|PubMed:23620513,
CC       ECO:0000269|PubMed:26387950, ECO:0000269|PubMed:30448281,
CC       ECO:0000269|PubMed:7891887, ECO:0000269|PubMed:7972031,
CC       ECO:0000269|PubMed:8340399, ECO:0000269|PubMed:8367470}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with hepatitis C virus (HCV)
CC       envelope glycoprotein E2; this interaction is required for HCV
CC       infectivity and production. {ECO:0000269|PubMed:25122793,
CC       ECO:0000269|PubMed:29695434}.
CC   -!- INTERACTION:
CC       P02649; Q9UIJ7: AK3; NbExp=3; IntAct=EBI-1222467, EBI-3916527;
CC       P02649; Q06481-5: APLP2; NbExp=3; IntAct=EBI-1222467, EBI-25646567;
CC       P02649; PRO_0000000093 [P05067]: APP; NbExp=4; IntAct=EBI-1222467, EBI-2431589;
CC       P02649; Q9HBG4: ATP6V0A4; NbExp=3; IntAct=EBI-1222467, EBI-25832286;
CC       P02649; Q9NUB4: C20orf141; NbExp=3; IntAct=EBI-1222467, EBI-9088162;
CC       P02649; P02748: C9; NbExp=2; IntAct=EBI-1222467, EBI-6677628;
CC       P02649; Q16543: CDC37; NbExp=3; IntAct=EBI-1222467, EBI-295634;
CC       P02649; P08603: CFH; NbExp=8; IntAct=EBI-1222467, EBI-1223708;
CC       P02649; Q9UBD9: CLCF1; NbExp=3; IntAct=EBI-1222467, EBI-2880701;
CC       P02649; Q8IUW6: CLSTN3; NbExp=3; IntAct=EBI-1222467, EBI-25832219;
CC       P02649; P26441: CNTF; NbExp=3; IntAct=EBI-1222467, EBI-1050897;
CC       P02649; Q9H6J7-2: CSTPP1; NbExp=3; IntAct=EBI-1222467, EBI-13328871;
CC       P02649; Q9H816: DCLRE1B; NbExp=3; IntAct=EBI-1222467, EBI-3508943;
CC       P02649; Q9BQ95: ECSIT; NbExp=4; IntAct=EBI-1222467, EBI-712452;
CC       P02649; Q9Y6C2-2: EMILIN1; NbExp=3; IntAct=EBI-1222467, EBI-11748557;
CC       P02649; Q3SYB3: FOXD4L6; NbExp=3; IntAct=EBI-1222467, EBI-6425864;
CC       P02649; Q8IY40: GRIK2; NbExp=3; IntAct=EBI-1222467, EBI-25832107;
CC       P02649; O75409: H2AP; NbExp=3; IntAct=EBI-1222467, EBI-6447217;
CC       P02649; P00738: HP; NbExp=7; IntAct=EBI-1222467, EBI-1220767;
CC       P02649; Q9BYZ2: LDHAL6B; NbExp=3; IntAct=EBI-1222467, EBI-1108377;
CC       P02649; P01130: LDLR; NbExp=4; IntAct=EBI-1222467, EBI-988319;
CC       P02649; P09382: LGALS1; NbExp=3; IntAct=EBI-1222467, EBI-1048875;
CC       P02649; Q07954: LRP1; NbExp=23; IntAct=EBI-1222467, EBI-1046087;
CC       P02649; Q14114: LRP8; NbExp=2; IntAct=EBI-1222467, EBI-2681187;
CC       P02649; Q14114-3: LRP8; NbExp=3; IntAct=EBI-1222467, EBI-25832196;
CC       P02649; P11137-4: MAP2; NbExp=3; IntAct=EBI-1222467, EBI-25832133;
CC       P02649; P10636-6: MAPT; NbExp=3; IntAct=EBI-1222467, EBI-7796455;
CC       P02649; Q9Y3D2: MSRB2; NbExp=3; IntAct=EBI-1222467, EBI-9092052;
CC       P02649; P02795: MT2A; NbExp=3; IntAct=EBI-1222467, EBI-996616;
CC       P02649; Q53EL6: PDCD4; NbExp=3; IntAct=EBI-1222467, EBI-935824;
CC       P02649; Q9NS23-4: RASSF1; NbExp=3; IntAct=EBI-1222467, EBI-438710;
CC       P02649; P52756: RBM5; NbExp=3; IntAct=EBI-1222467, EBI-714003;
CC       P02649; Q6ZNA4-2: RNF111; NbExp=3; IntAct=EBI-1222467, EBI-21535400;
CC       P02649; Q8WTV0-2: SCARB1; NbExp=3; IntAct=EBI-1222467, EBI-21529758;
CC       P02649; P37840: SNCA; NbExp=11; IntAct=EBI-1222467, EBI-985879;
CC       P02649; Q8IUW3: SPATA2L; NbExp=3; IntAct=EBI-1222467, EBI-2510414;
CC       P02649; P50502: ST13; NbExp=3; IntAct=EBI-1222467, EBI-357285;
CC       P02649; O75069: TMCC2; NbExp=5; IntAct=EBI-1222467, EBI-726731;
CC       P02649; Q13829: TNFAIP1; NbExp=3; IntAct=EBI-1222467, EBI-2505861;
CC       P02649; Q9NZC2: TREM2; NbExp=4; IntAct=EBI-1222467, EBI-14036387;
CC       P02649; Q6PID6: TTC33; NbExp=3; IntAct=EBI-1222467, EBI-2555404;
CC       P02649; Q8TBC4: UBA3; NbExp=3; IntAct=EBI-1222467, EBI-717567;
CC       P02649; Q9NYH9: UTP6; NbExp=3; IntAct=EBI-1222467, EBI-749211;
CC       P02649; P21796: VDAC1; NbExp=2; IntAct=EBI-1222467, EBI-354158;
CC       P02649; P17028: ZNF24; NbExp=3; IntAct=EBI-1222467, EBI-707773;
CC       P02649; PRO_0000037570 [P27958]; Xeno; NbExp=4; IntAct=EBI-1222467, EBI-6904269;
CC       PRO_0000001987; P10636: MAPT; NbExp=3; IntAct=EBI-9209835, EBI-366182;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:2498325,
CC       ECO:0000269|PubMed:30333625}. Secreted, extracellular space
CC       {ECO:0000269|PubMed:8340399}. Secreted, extracellular space,
CC       extracellular matrix {ECO:0000269|PubMed:9488694}. Extracellular
CC       vesicle {ECO:0000269|PubMed:26387950}. Endosome, multivesicular body
CC       {ECO:0000269|PubMed:26387950}. Note=In the plasma, APOE is associated
CC       with chylomicrons, chylomicrons remnants, VLDL, LDL and HDL
CC       lipoproteins (PubMed:1911868, PubMed:8340399). Lipid poor oligomeric
CC       APOE is associated with the extracellular matrix in a calcium- and
CC       heparan-sulfate proteoglycans-dependent manner (PubMed:9488694).
CC       Lipidation induces the release from the extracellular matrix
CC       (PubMed:9488694). Colocalizes with CD63 and PMEL at exosomes and in
CC       intraluminal vesicles within multivesicular endosomes.
CC       {ECO:0000269|PubMed:1911868, ECO:0000269|PubMed:26387950,
CC       ECO:0000269|PubMed:8340399, ECO:0000269|PubMed:9488694}.
CC   -!- TISSUE SPECIFICITY: Produced by several tissues and cell types and
CC       mainly found associated with lipid particles in the plasma, the
CC       interstitial fluid and lymph (PubMed:25173806). Mainly synthesized by
CC       liver hepatocytes (PubMed:25173806). Significant quantities are also
CC       produced in brain, mainly by astrocytes and glial cells in the cerebral
CC       cortex, but also by neurons in frontal cortex and hippocampus
CC       (PubMed:10027417, PubMed:3115992). It is also expressed by cells of the
CC       peripheral nervous system (PubMed:10027417, PubMed:25173806). Also
CC       expressed by adrenal gland, testis, ovary, skin, kidney, spleen and
CC       adipose tissue and macrophages in various tissues (PubMed:25173806).
CC       {ECO:0000269|PubMed:10027417, ECO:0000269|PubMed:3115992,
CC       ECO:0000303|PubMed:25173806}.
CC   -!- PTM: APOE exists as multiple glycosylated and sialylated glycoforms
CC       within cells and in plasma (PubMed:29516132). The extent of
CC       glycosylation and sialylation are tissue and context specific
CC       (PubMed:29516132). Plasma APOE undergoes desialylation and is less
CC       glycosylated and sialylated than the cellular form (PubMed:19838169,
CC       PubMed:20511397, PubMed:23234360, PubMed:2498325). Glycosylation is not
CC       required for proper expression and secretion (PubMed:2498325). O-
CC       glycosylated with core 1 or possibly core 8 glycans. Thr-307 and Ser-
CC       314 are minor glycosylation sites compared to Ser-308 (PubMed:19838169,
CC       PubMed:23234360). {ECO:0000269|PubMed:19838169,
CC       ECO:0000269|PubMed:20511397, ECO:0000269|PubMed:23234360,
CC       ECO:0000269|PubMed:2498325, ECO:0000303|PubMed:29516132}.
CC   -!- PTM: Glycated in plasma VLDL of normal subjects, and of hyperglycemic
CC       diabetic patients at a higher level (2-3 fold).
CC       {ECO:0000269|PubMed:10452964}.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000269|PubMed:26091039}.
CC   -!- PTM: Undergoes C-terminal proteolytic processing in neurons. C-
CC       terminally truncated APOE has a tendency to form neurotoxic
CC       intracellular neurofibrillary tangle-like inclusions in neurons.
CC       {ECO:0000269|PubMed:11447277}.
CC   -!- POLYMORPHISM: There are three common APOE alleles identified:
CC       APOE*2/APOE-epsilon2/E2, APOE*3/APOE-epsilon3/E3, and APOE*4/APOE-
CC       epsilon4/E4. The corresponding ApoE2, ApoE3 and ApoE4 isoforms
CC       differentially present Cys and Arg residues at positions 130 and 176.
CC       The most common allele in the human population is APOE*3 which sequence
CC       is the one displayed in that entry with a Cys at position 130 and an
CC       Arg at position 176. Common APOE variants influence lipoprotein
CC       metabolism in healthy individuals. Additional variants have been
CC       described and are described relative to the three common alleles.
CC       Allele APOE*4 is strongly associated with risk for severe COVID-19,
CC       increases susceptibility to SARS-CoV-2 infection in neurons and
CC       astrocytes (PubMed:33450186). {ECO:0000269|PubMed:2987927,
CC       ECO:0000269|PubMed:3243553, ECO:0000269|PubMed:33450186,
CC       ECO:0000269|PubMed:6325438, ECO:0000303|PubMed:25173806}.
CC   -!- DISEASE: Hyperlipoproteinemia 3 (HLPP3) [MIM:617347]: A disorder
CC       characterized by the accumulation of intermediate-density lipoprotein
CC       particles (IDL or broad-beta-lipoprotein) rich in cholesterol. Clinical
CC       features include xanthomas, yellowish lipid deposits in the palmar
CC       crease, or less specific on tendons and on elbows. The disorder rarely
CC       manifests before the third decade in men. In women, it is usually
CC       expressed only after the menopause. {ECO:0000269|PubMed:1361196,
CC       ECO:0000269|PubMed:1674745, ECO:0000269|PubMed:2101409,
CC       ECO:0000269|PubMed:22481068, ECO:0000269|PubMed:2556398,
CC       ECO:0000269|PubMed:26802169, ECO:0000269|PubMed:2738044,
CC       ECO:0000269|PubMed:7635945, ECO:0000269|PubMed:8287539}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry. The vast majority of the patients are homozygous for APOE*2
CC       alleles. More severe cases of HLPP3 have also been observed in
CC       individuals heterozygous for rare APOE variants. The influence of APOE
CC       on lipid levels is often suggested to have major implications for the
CC       risk of coronary artery disease (CAD). Individuals carrying the common
CC       APOE*4 variant are at higher risk of CAD.
CC   -!- DISEASE: Alzheimer disease 2 (AD2) [MIM:104310]: A late-onset form of
CC       Alzheimer disease. Alzheimer disease is a neurodegenerative disorder
CC       characterized by progressive dementia, loss of cognitive abilities, and
CC       deposition of fibrillar amyloid proteins as intraneuronal
CC       neurofibrillary tangles, extracellular amyloid plaques and vascular
CC       amyloid deposits. The major constituents of these plaques are
CC       neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that
CC       are produced by the proteolysis of the transmembrane APP protein. The
CC       cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products,
CC       such as C31, are also implicated in neuronal death.
CC       {ECO:0000269|PubMed:10903326, ECO:0000269|PubMed:11258893,
CC       ECO:0000269|PubMed:11447277, ECO:0000269|PubMed:28111074,
CC       ECO:0000269|PubMed:2987927, ECO:0000269|PubMed:7891887,
CC       ECO:0000269|PubMed:7972031, ECO:0000269|PubMed:8071364,
CC       ECO:0000269|PubMed:8346443, ECO:0000269|PubMed:8367470,
CC       ECO:0000269|PubMed:8939961}. Note=Disease susceptibility is associated
CC       with variants affecting the gene represented in this entry. The APOE*4
CC       allele (APOE form E4) is genetically associated with the common late
CC       onset familial and sporadic forms of Alzheimer disease. Risk for AD
CC       increased from 20% to 90% and mean age at onset decreased from 84 to 68
CC       years with increasing number of APOE*4 alleles in 42 families with late
CC       onset AD. Thus APOE*4 gene dose is a major risk factor for late onset
CC       AD and, in these families, homozygosity for APOE*4 was virtually
CC       sufficient to cause AD by age 80. The mechanism by which APOE*4
CC       participates in pathogenesis is not known.
CC       {ECO:0000269|PubMed:8346443}.
CC   -!- DISEASE: Sea-blue histiocyte disease (SBHD) [MIM:269600]: Characterized
CC       by splenomegaly, mild thrombocytopenia and, in the bone marrow,
CC       numerous histiocytes containing cytoplasmic granules which stain bright
CC       blue with the usual hematologic stains. The syndrome is the consequence
CC       of an inherited metabolic defect analogous to Gaucher disease and other
CC       sphingolipidoses. {ECO:0000269|PubMed:11095479,
CC       ECO:0000269|PubMed:16094309, ECO:0000269|PubMed:22481068,
CC       ECO:0000269|PubMed:22949395, ECO:0000269|PubMed:24267230,
CC       ECO:0000269|PubMed:26802169}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Lipoprotein glomerulopathy (LPG) [MIM:611771]: Uncommon kidney
CC       disease characterized by proteinuria, progressive kidney failure, and
CC       distinctive lipoprotein thrombi in glomerular capillaries.
CC       {ECO:0000269|PubMed:10432380, ECO:0000269|PubMed:10903326,
CC       ECO:0000269|PubMed:18077821, ECO:0000269|PubMed:9176854}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: Binds to and activates LILRB4 on acute myeloid leukemia
CC       (AML) cells which leads to suppression of T cell proliferation and
CC       promotion of AML cell migration and infiltration.
CC       {ECO:0000269|PubMed:30333625}.
CC   -!- SIMILARITY: Belongs to the apolipoprotein A1/A4/E family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Apolipoprotein E entry;
CC       URL="https://en.wikipedia.org/wiki/Apolipoprotein_E";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Tangled - Issue 83 of June
CC       2007;
CC       URL="https://web.expasy.org/spotlight/back_issues/083";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M12529; AAB59518.1; -; mRNA.
DR   EMBL; K00396; AAB59546.1; -; mRNA.
DR   EMBL; M10065; AAB59397.1; -; Genomic_DNA.
DR   EMBL; AF050154; AAD02505.1; -; Genomic_DNA.
DR   EMBL; AF261279; AAG27089.1; -; Genomic_DNA.
DR   EMBL; AK314898; BAG37412.1; -; mRNA.
DR   EMBL; FJ525876; ACN81314.1; -; Genomic_DNA.
DR   EMBL; BC003557; AAH03557.1; -; mRNA.
DR   EMBL; AB035149; BAA96080.1; -; Genomic_DNA.
DR   CCDS; CCDS12647.1; -.
DR   PIR; A92478; LPHUE.
DR   RefSeq; NP_000032.1; NM_000041.3.
DR   RefSeq; NP_001289617.1; NM_001302688.1.
DR   RefSeq; NP_001289618.1; NM_001302689.1.
DR   RefSeq; NP_001289619.1; NM_001302690.1.
DR   RefSeq; NP_001289620.1; NM_001302691.1.
DR   PDB; 1B68; X-ray; 2.00 A; A=19-209.
DR   PDB; 1BZ4; X-ray; 1.85 A; A=40-183.
DR   PDB; 1EA8; X-ray; 1.95 A; A=19-209.
DR   PDB; 1GS9; X-ray; 1.70 A; A=19-183.
DR   PDB; 1H7I; X-ray; 1.90 A; A=19-209.
DR   PDB; 1LE2; X-ray; 3.00 A; A=41-184.
DR   PDB; 1LE4; X-ray; 2.50 A; A=41-184.
DR   PDB; 1LPE; X-ray; 2.25 A; A=41-184.
DR   PDB; 1NFN; X-ray; 1.80 A; A=19-209.
DR   PDB; 1NFO; X-ray; 2.00 A; A=19-209.
DR   PDB; 1OEF; NMR; -; A=281-304.
DR   PDB; 1OEG; NMR; -; A=285-307.
DR   PDB; 1OR2; X-ray; 2.50 A; A=19-183.
DR   PDB; 1OR3; X-ray; 1.73 A; A=19-183.
DR   PDB; 2KC3; NMR; -; A=19-201.
DR   PDB; 2KNY; NMR; -; A=147-167.
DR   PDB; 2L7B; NMR; -; A=19-317.
DR   PDB; 6IWB; X-ray; 2.50 A; A/C=41-186.
DR   PDB; 6NCN; X-ray; 1.82 A; A=19-180.
DR   PDB; 6NCO; X-ray; 1.71 A; A=19-180.
DR   PDB; 7FCR; X-ray; 1.40 A; A=19-209.
DR   PDB; 7FCS; X-ray; 1.60 A; A=19-209.
DR   PDB; 7UVJ; X-ray; 1.99 A; A/B=40-183.
DR   PDB; 8AX8; X-ray; 1.55 A; A=19-317.
DR   PDB; 8AX9; X-ray; 1.55 A; A=19-317.
DR   PDB; 8CDY; X-ray; 1.90 A; A=19-317.
DR   PDB; 8CE0; X-ray; 1.75 A; A=19-317.
DR   PDB; 8GRX; EM; 3.00 A; A/C=41-180.
DR   PDBsum; 1B68; -.
DR   PDBsum; 1BZ4; -.
DR   PDBsum; 1EA8; -.
DR   PDBsum; 1GS9; -.
DR   PDBsum; 1H7I; -.
DR   PDBsum; 1LE2; -.
DR   PDBsum; 1LE4; -.
DR   PDBsum; 1LPE; -.
DR   PDBsum; 1NFN; -.
DR   PDBsum; 1NFO; -.
DR   PDBsum; 1OEF; -.
DR   PDBsum; 1OEG; -.
DR   PDBsum; 1OR2; -.
DR   PDBsum; 1OR3; -.
DR   PDBsum; 2KC3; -.
DR   PDBsum; 2KNY; -.
DR   PDBsum; 2L7B; -.
DR   PDBsum; 6IWB; -.
DR   PDBsum; 6NCN; -.
DR   PDBsum; 6NCO; -.
DR   PDBsum; 7FCR; -.
DR   PDBsum; 7FCS; -.
DR   PDBsum; 7UVJ; -.
DR   PDBsum; 8AX8; -.
DR   PDBsum; 8AX9; -.
DR   PDBsum; 8CDY; -.
DR   PDBsum; 8CE0; -.
DR   PDBsum; 8GRX; -.
DR   AlphaFoldDB; P02649; -.
DR   BMRB; P02649; -.
DR   EMDB; EMD-34216; -.
DR   SASBDB; P02649; -.
DR   SMR; P02649; -.
DR   BioGRID; 106845; 154.
DR   DIP; DIP-1120N; -.
DR   IntAct; P02649; 95.
DR   MINT; P02649; -.
DR   STRING; 9606.ENSP00000252486; -.
DR   DrugBank; DB09130; Copper.
DR   DrugBank; DB11886; Infigratinib.
DR   DrugBank; DB00877; Sirolimus.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   DrugBank; DB14533; Zinc chloride.
DR   DrugBank; DB14548; Zinc sulfate, unspecified form.
DR   MoonDB; P02649; Predicted.
DR   TCDB; 9.B.445.2.1; the apolipoprotein a2 (alp-a2) family.
DR   CarbonylDB; P02649; -.
DR   GlyConnect; 648; 2 O-Linked glycans (5 sites).
DR   GlyCosmos; P02649; 8 sites, 5 glycans.
DR   GlyGen; P02649; 8 sites, 7 O-linked glycans (8 sites).
DR   iPTMnet; P02649; -.
DR   MetOSite; P02649; -.
DR   PhosphoSitePlus; P02649; -.
DR   SwissPalm; P02649; -.
DR   BioMuta; APOE; -.
DR   DMDM; 114039; -.
DR   CPTAC; non-CPTAC-1087; -.
DR   jPOST; P02649; -.
DR   MassIVE; P02649; -.
DR   PaxDb; 9606-ENSP00000252486; -.
DR   PeptideAtlas; P02649; -.
DR   ProteomicsDB; 51537; -.
DR   Pumba; P02649; -.
DR   ABCD; P02649; 7 sequenced antibodies.
DR   Antibodypedia; 3639; 1551 antibodies from 50 providers.
DR   DNASU; 348; -.
DR   Ensembl; ENST00000252486.9; ENSP00000252486.3; ENSG00000130203.10.
DR   GeneID; 348; -.
DR   KEGG; hsa:348; -.
DR   MANE-Select; ENST00000252486.9; ENSP00000252486.3; NM_000041.4; NP_000032.1.
DR   UCSC; uc002pab.4; human.
DR   AGR; HGNC:613; -.
DR   CTD; 348; -.
DR   DisGeNET; 348; -.
DR   GeneCards; APOE; -.
DR   HGNC; HGNC:613; APOE.
DR   HPA; ENSG00000130203; Group enriched (adrenal gland, brain, liver).
DR   MalaCards; APOE; -.
DR   MIM; 104310; phenotype.
DR   MIM; 107741; gene.
DR   MIM; 269600; phenotype.
DR   MIM; 611771; phenotype.
DR   MIM; 617347; phenotype.
DR   neXtProt; NX_P02649; -.
DR   NIAGADS; ENSG00000130203; -.
DR   OpenTargets; ENSG00000130203; -.
DR   Orphanet; 412; Dysbetalipoproteinemia.
DR   Orphanet; 329481; Lipoprotein glomerulopathy.
DR   Orphanet; 238616; NON RARE IN EUROPE: Alzheimer disease.
DR   Orphanet; 1648; NON RARE IN EUROPE: Dementia with Lewy body.
DR   Orphanet; 158029; Sea-blue histiocytosis.
DR   PharmGKB; PA55; -.
DR   VEuPathDB; HostDB:ENSG00000130203; -.
DR   eggNOG; ENOG502QVD6; Eukaryota.
DR   GeneTree; ENSGT00950000182929; -.
DR   HOGENOM; CLU_066029_0_0_1; -.
DR   InParanoid; P02649; -.
DR   OMA; GHMTDAR; -.
DR   OrthoDB; 4591103at2759; -.
DR   PhylomeDB; P02649; -.
DR   TreeFam; TF334458; -.
DR   PathwayCommons; P02649; -.
DR   Reactome; R-HSA-1251985; Nuclear signaling by ERBB4.
DR   Reactome; R-HSA-3000480; Scavenging by Class A Receptors.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-8864260; Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors.
DR   Reactome; R-HSA-8957275; Post-translational protein phosphorylation.
DR   Reactome; R-HSA-8963888; Chylomicron assembly.
DR   Reactome; R-HSA-8963901; Chylomicron remodeling.
DR   Reactome; R-HSA-8964026; Chylomicron clearance.
DR   Reactome; R-HSA-8964058; HDL remodeling.
DR   Reactome; R-HSA-9029569; NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   SignaLink; P02649; -.
DR   SIGNOR; P02649; -.
DR   BioGRID-ORCS; 348; 20 hits in 1163 CRISPR screens.
DR   ChiTaRS; APOE; human.
DR   EvolutionaryTrace; P02649; -.
DR   GeneWiki; Apolipoprotein_E; -.
DR   GenomeRNAi; 348; -.
DR   Pharos; P02649; Tbio.
DR   PRO; PR:P02649; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P02649; protein.
DR   Bgee; ENSG00000130203; Expressed in right adrenal gland cortex and 179 other cell types or tissues.
DR   ExpressionAtlas; P02649; baseline and differential.
DR   GO; GO:0072562; C:blood microparticle; HDA:UniProtKB.
DR   GO; GO:0042627; C:chylomicron; IDA:BHF-UCL.
DR   GO; GO:0034360; C:chylomicron remnant; IDA:ARUK-UCL.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0030425; C:dendrite; NAS:BHF-UCL.
DR   GO; GO:0034365; C:discoidal high-density lipoprotein particle; TAS:ARUK-UCL.
DR   GO; GO:0005769; C:early endosome; TAS:Reactome.
DR   GO; GO:0071682; C:endocytic vesicle lumen; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:AgBase.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:ARUK-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:1903561; C:extracellular vesicle; HDA:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:AgBase.
DR   GO; GO:0034364; C:high-density lipoprotein particle; IDA:UniProtKB.
DR   GO; GO:0034363; C:intermediate-density lipoprotein particle; IDA:UniProtKB.
DR   GO; GO:1990777; C:lipoprotein particle; IDA:ARUK-UCL.
DR   GO; GO:0034362; C:low-density lipoprotein particle; IDA:UniProtKB.
DR   GO; GO:0042470; C:melanosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0097487; C:multivesicular body, internal vesicle; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; NAS:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043083; C:synaptic cleft; IDA:SynGO.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; IDA:UniProtKB.
DR   GO; GO:0001540; F:amyloid-beta binding; IDA:UniProtKB.
DR   GO; GO:0016209; F:antioxidant activity; IDA:BHF-UCL.
DR   GO; GO:0120020; F:cholesterol transfer activity; IBA:GO_Central.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; IDA:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IDA:UniProtKB.
DR   GO; GO:0008289; F:lipid binding; IDA:UniProtKB.
DR   GO; GO:0005319; F:lipid transporter activity; IDA:BHF-UCL.
DR   GO; GO:0071813; F:lipoprotein particle binding; IEA:Ensembl.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; IDA:UniProtKB.
DR   GO; GO:0046911; F:metal chelating activity; IDA:BHF-UCL.
DR   GO; GO:0060228; F:phosphatidylcholine-sterol O-acyltransferase activator activity; IDA:BHF-UCL.
DR   GO; GO:0005543; F:phospholipid binding; IDA:BHF-UCL.
DR   GO; GO:0046983; F:protein dimerization activity; IPI:ARUK-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:ARUK-UCL.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:ARUK-UCL.
DR   GO; GO:0048018; F:receptor ligand activity; IDA:UniProt.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:ARUK-UCL.
DR   GO; GO:0005198; F:structural molecule activity; TAS:ARUK-UCL.
DR   GO; GO:0048156; F:tau protein binding; IPI:BHF-UCL.
DR   GO; GO:0070326; F:very-low-density lipoprotein particle receptor binding; IDA:BHF-UCL.
DR   GO; GO:0055090; P:acylglycerol homeostasis; IBA:GO_Central.
DR   GO; GO:0097113; P:AMPA glutamate receptor clustering; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0042982; P:amyloid precursor protein metabolic process; IDA:UniProtKB.
DR   GO; GO:0048844; P:artery morphogenesis; IEA:Ensembl.
DR   GO; GO:0071402; P:cellular response to lipoprotein particle stimulus; IDA:UniProt.
DR   GO; GO:0006707; P:cholesterol catabolic process; IEA:Ensembl.
DR   GO; GO:0033344; P:cholesterol efflux; IDA:UniProtKB.
DR   GO; GO:0042632; P:cholesterol homeostasis; IDA:BHF-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; IDA:BHF-UCL.
DR   GO; GO:0034382; P:chylomicron remnant clearance; IDA:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0055089; P:fatty acid homeostasis; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0010467; P:gene expression; IEA:Ensembl.
DR   GO; GO:0034380; P:high-density lipoprotein particle assembly; IDA:UniProtKB.
DR   GO; GO:0034384; P:high-density lipoprotein particle clearance; IDA:BHF-UCL.
DR   GO; GO:0034375; P:high-density lipoprotein particle remodeling; IGI:BHF-UCL.
DR   GO; GO:0071831; P:intermediate-density lipoprotein particle clearance; IDA:UniProtKB.
DR   GO; GO:0006874; P:intracellular calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0046907; P:intracellular transport; TAS:UniProtKB.
DR   GO; GO:0010877; P:lipid transport involved in lipid storage; ISS:BHF-UCL.
DR   GO; GO:0042158; P:lipoprotein biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0042159; P:lipoprotein catabolic process; IEA:Ensembl.
DR   GO; GO:0035641; P:locomotory exploration behavior; IMP:ARUK-UCL.
DR   GO; GO:0015909; P:long-chain fatty acid transport; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0007616; P:long-term memory; IGI:ARUK-UCL.
DR   GO; GO:0034374; P:low-density lipoprotein particle remodeling; IEA:Ensembl.
DR   GO; GO:0051651; P:maintenance of location in cell; IEA:Ensembl.
DR   GO; GO:0032438; P:melanosome organization; IMP:UniProtKB.
DR   GO; GO:1905907; P:negative regulation of amyloid fibril formation; ISS:UniProtKB.
DR   GO; GO:1902430; P:negative regulation of amyloid-beta formation; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0030195; P:negative regulation of blood coagulation; IDA:BHF-UCL.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:ARUK-UCL.
DR   GO; GO:0045541; P:negative regulation of cholesterol biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0010596; P:negative regulation of endothelial cell migration; IMP:ARUK-UCL.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISS:ARUK-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:1900272; P:negative regulation of long-term synaptic potentiation; IDA:ARUK-UCL.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IDA:BHF-UCL.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IDA:ARUK-UCL.
DR   GO; GO:0010544; P:negative regulation of platelet activation; IDA:BHF-UCL.
DR   GO; GO:0051248; P:negative regulation of protein metabolic process; IGI:ARUK-UCL.
DR   GO; GO:0050709; P:negative regulation of protein secretion; IMP:UniProtKB.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0090209; P:negative regulation of triglyceride metabolic process; IEA:Ensembl.
DR   GO; GO:0031175; P:neuron projection development; IDA:UniProtKB.
DR   GO; GO:0038060; P:nitric oxide-cGMP-mediated signaling; IDA:BHF-UCL.
DR   GO; GO:0097114; P:NMDA glutamate receptor clustering; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0033700; P:phospholipid efflux; IDA:BHF-UCL.
DR   GO; GO:0044794; P:positive regulation by host of viral process; IMP:AgBase.
DR   GO; GO:1905908; P:positive regulation of amyloid fibril formation; TAS:ARUK-UCL.
DR   GO; GO:1900223; P:positive regulation of amyloid-beta clearance; ISS:UniProtKB.
DR   GO; GO:0010875; P:positive regulation of cholesterol efflux; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0090205; P:positive regulation of cholesterol metabolic process; IDA:BHF-UCL.
DR   GO; GO:1905920; P:positive regulation of CoA-transferase activity; IDA:BHF-UCL.
DR   GO; GO:0060999; P:positive regulation of dendritic spine development; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1902952; P:positive regulation of dendritic spine maintenance; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:UniProtKB.
DR   GO; GO:0045807; P:positive regulation of endocytosis; IDA:ARUK-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:1905860; P:positive regulation of heparan sulfate proteoglycan binding; IDA:ARUK-UCL.
DR   GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1903002; P:positive regulation of lipid transport across blood-brain barrier; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0032805; P:positive regulation of low-density lipoprotein particle receptor catabolic process; IDA:BHF-UCL.
DR   GO; GO:0051044; P:positive regulation of membrane protein ectodomain proteolysis; IDA:BHF-UCL.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IDA:ARUK-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:1902995; P:positive regulation of phospholipid efflux; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0017038; P:protein import; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; IDA:BHF-UCL.
DR   GO; GO:1905906; P:regulation of amyloid fibril formation; IDA:ARUK-UCL.
DR   GO; GO:1902991; P:regulation of amyloid precursor protein catabolic process; IDA:UniProtKB.
DR   GO; GO:1900221; P:regulation of amyloid-beta clearance; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0042981; P:regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0030516; P:regulation of axon extension; TAS:UniProtKB.
DR   GO; GO:2000822; P:regulation of behavioral fear response; IMP:ARUK-UCL.
DR   GO; GO:0032489; P:regulation of Cdc42 protein signal transduction; IDA:BHF-UCL.
DR   GO; GO:1905890; P:regulation of cellular response to very-low-density lipoprotein particle stimulus; IDA:ARUK-UCL.
DR   GO; GO:0090181; P:regulation of cholesterol metabolic process; IGI:ARUK-UCL.
DR   GO; GO:0045088; P:regulation of innate immune response; IEA:Ensembl.
DR   GO; GO:0048168; P:regulation of neuronal synaptic plasticity; TAS:UniProtKB.
DR   GO; GO:0061136; P:regulation of proteasomal protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0051246; P:regulation of protein metabolic process; IGI:ARUK-UCL.
DR   GO; GO:0043254; P:regulation of protein-containing complex assembly; IDA:ARUK-UCL.
DR   GO; GO:0061771; P:response to caloric restriction; IGI:ARUK-UCL.
DR   GO; GO:0002021; P:response to dietary excess; IEA:Ensembl.
DR   GO; GO:0000302; P:response to reactive oxygen species; NAS:UniProtKB.
DR   GO; GO:0043691; P:reverse cholesterol transport; IDA:BHF-UCL.
DR   GO; GO:0007271; P:synaptic transmission, cholinergic; TAS:UniProtKB.
DR   GO; GO:0070328; P:triglyceride homeostasis; ISS:BHF-UCL.
DR   GO; GO:0006641; P:triglyceride metabolic process; IDA:BHF-UCL.
DR   GO; GO:0071830; P:triglyceride-rich lipoprotein particle clearance; IMP:UniProtKB.
DR   GO; GO:0042311; P:vasodilation; IEA:Ensembl.
DR   GO; GO:0034447; P:very-low-density lipoprotein particle clearance; IDA:UniProtKB.
DR   GO; GO:0034372; P:very-low-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   GO; GO:0019068; P:virion assembly; IMP:AgBase.
DR   Gene3D; 1.20.120.20; Apolipoprotein; 2.
DR   InterPro; IPR000074; ApoA_E.
DR   InterPro; IPR050163; Apolipoprotein_A1/A4/E.
DR   PANTHER; PTHR18976; APOLIPOPROTEIN; 1.
DR   PANTHER; PTHR18976:SF2; APOLIPOPROTEIN E; 1.
DR   Pfam; PF01442; Apolipoprotein; 1.
DR   SUPFAM; SSF58113; Apolipoprotein A-I; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alzheimer disease; Amyloidosis; Cholesterol metabolism;
KW   Chylomicron; Direct protein sequencing; Disease variant; Endosome;
KW   Extracellular matrix; Glycation; Glycoprotein; HDL; Heparin-binding;
KW   Host-virus interaction; Hyperlipidemia; Lipid metabolism; Lipid transport;
KW   Lipid-binding; Neurodegeneration; Oxidation; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Repeat; Secreted; Signal;
KW   Steroid metabolism; Sterol metabolism; Transport; VLDL.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000269|PubMed:7068630"
FT   CHAIN           19..317
FT                   /note="Apolipoprotein E"
FT                   /id="PRO_0000001987"
FT   REPEAT          80..101
FT                   /note="1"
FT   REPEAT          102..123
FT                   /note="2"
FT   REPEAT          124..145
FT                   /note="3"
FT   REPEAT          146..167
FT                   /note="4"
FT   REPEAT          168..189
FT                   /note="5"
FT   REPEAT          190..211
FT                   /note="6"
FT   REPEAT          212..233
FT                   /note="7"
FT   REPEAT          234..255
FT                   /note="8"
FT   REGION          80..255
FT                   /note="8 X 22 AA approximate tandem repeats"
FT   REGION          158..168
FT                   /note="LDL and other lipoprotein receptors binding"
FT                   /evidence="ECO:0000269|PubMed:20030366,
FT                   ECO:0000269|PubMed:2063194"
FT   REGION          210..290
FT                   /note="Lipid-binding and lipoprotein association"
FT                   /evidence="ECO:0000269|PubMed:2280190,
FT                   ECO:0000269|PubMed:8071364"
FT   REGION          266..317
FT                   /note="Homooligomerization"
FT                   /evidence="ECO:0000269|PubMed:8340399"
FT   REGION          278..290
FT                   /note="Specificity for association with VLDL"
FT                   /evidence="ECO:0000269|PubMed:8071364"
FT   BINDING         162..165
FT                   /ligand="heparin"
FT                   /ligand_id="ChEBI:CHEBI:28304"
FT                   /evidence="ECO:0000269|PubMed:3947350"
FT   BINDING         229..236
FT                   /ligand="heparin"
FT                   /ligand_id="ChEBI:CHEBI:28304"
FT                   /evidence="ECO:0000269|PubMed:3947350"
FT   MOD_RES         143
FT                   /note="Methionine sulfoxide"
FT                   /evidence="ECO:0000250|UniProtKB:P08226"
FT   MOD_RES         147
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:26091039,
FT                   ECO:0007744|PubMed:24275569"
FT   CARBOHYD        26
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:23234360"
FT   CARBOHYD        36
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:23234360"
FT   CARBOHYD        93
FT                   /note="N-linked (Glc) (glycation) lysine"
FT                   /evidence="ECO:0000269|PubMed:10452964"
FT   CARBOHYD        212
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:19838169,
FT                   ECO:0000269|PubMed:2498325"
FT   CARBOHYD        307
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:19838169"
FT   CARBOHYD        308
FT                   /note="O-linked (GalNAc...) serine"
FT                   /evidence="ECO:0000269|PubMed:19838169,
FT                   ECO:0000269|PubMed:20511397"
FT   CARBOHYD        314
FT                   /note="O-linked (GalNAc...) serine"
FT                   /evidence="ECO:0000269|PubMed:23234360"
FT   VARIANT         21
FT                   /note="E -> K (in ApoE5; associated with
FT                   hyperlipoproteinemia and atherosclerosis; increased binding
FT                   to LDL receptor; dbSNP:rs121918392)"
FT                   /evidence="ECO:0000269|PubMed:1530612,
FT                   ECO:0000269|PubMed:2760009"
FT                   /id="VAR_000645"
FT   VARIANT         31
FT                   /note="E -> K (in HLPP3; ApoE4 Philadelphia, ApoE5
FT                   French-Canadian and ApoE5-type; only ApoE4 Philadelphia is
FT                   associated with HLPP3; dbSNP:rs201672011)"
FT                   /evidence="ECO:0000269|PubMed:1674745,
FT                   ECO:0000269|PubMed:1713245, ECO:0000303|PubMed:7833947"
FT                   /id="VAR_000646"
FT   VARIANT         43
FT                   /note="R -> C (in LPG; ApoE2 Kyoto; dbSNP:rs121918399)"
FT                   /evidence="ECO:0000269|PubMed:10432380,
FT                   ECO:0000269|PubMed:18077821"
FT                   /id="VAR_042734"
FT   VARIANT         46
FT                   /note="L -> P (found in a patient with
FT                   hypercholesterolemia; uncertain significance; ApoE4
FT                   Freiburg; dbSNP:rs769452)"
FT                   /evidence="ECO:0000269|PubMed:11042151,
FT                   ECO:0000269|PubMed:26802169"
FT                   /id="VAR_000647"
FT   VARIANT         60
FT                   /note="T -> A (in ApoE3 Freiburg; dbSNP:rs28931576)"
FT                   /id="VAR_000648"
FT   VARIANT         64
FT                   /note="Q -> H (confirmed at protein level;
FT                   dbSNP:rs370594287)"
FT                   /evidence="ECO:0000269|PubMed:22028381, ECO:0000269|Ref.10"
FT                   /id="VAR_014114"
FT   VARIANT         99
FT                   /note="Q -> K (in ApoE5 Frankfurt; dbSNP:rs1180612218)"
FT                   /evidence="ECO:0000269|PubMed:8125051"
FT                   /id="VAR_000649"
FT   VARIANT         102
FT                   /note="P -> R (in ApoE5-type; no hyperlipidemia;
FT                   dbSNP:rs11083750)"
FT                   /evidence="ECO:0000303|PubMed:7833947"
FT                   /id="VAR_000650"
FT   VARIANT         117
FT                   /note="A -> T (in ApoE3*; dbSNP:rs28931577)"
FT                   /evidence="ECO:0000269|PubMed:6327682"
FT                   /id="VAR_000651"
FT   VARIANT         124
FT                   /note="A -> V (in ApoE3 Basel; dbSNP:rs937063425)"
FT                   /evidence="ECO:0000269|PubMed:12864777"
FT                   /id="VAR_016789"
FT   VARIANT         130
FT                   /note="C -> R (in HLPP3 and AD2; ApoE4, ApoE3 Leiden,
FT                   ApoE3**, ApoE5-Frankfurt and ApoE5-type; ApoE3 Leiden and
FT                   ApoE3** are associated with HLPP3; ApoE4 is associated with
FT                   AD2; changed protein structure; no effect on binding to LDL
FT                   receptor; decreased association with HDL and enrichment in
FT                   VLDL and IDL; may prevent the interaction with MAP2 and
FT                   MAPT; changed interaction with APP/A4 amyloid-beta peptide;
FT                   increased ability to induce APP transcription; increased
FT                   C-terminal proteolytic processing in neurons; decreased
FT                   function in neurite outgrowth; ApoE4 is associated with
FT                   higher susceptibility to SARS-CoV-2 infection in neurons
FT                   and astrocytes; dbSNP:rs429358)"
FT                   /evidence="ECO:0000269|PubMed:10903326,
FT                   ECO:0000269|PubMed:11042151, ECO:0000269|PubMed:11447277,
FT                   ECO:0000269|PubMed:12966036, ECO:0000269|PubMed:2280190,
FT                   ECO:0000269|PubMed:2556398, ECO:0000269|PubMed:28111074,
FT                   ECO:0000269|PubMed:2987927, ECO:0000269|PubMed:7891887,
FT                   ECO:0000269|PubMed:7972031, ECO:0000269|PubMed:8071364,
FT                   ECO:0000269|PubMed:8125051, ECO:0000269|PubMed:8287539,
FT                   ECO:0000269|PubMed:8346443, ECO:0000269|PubMed:8367470,
FT                   ECO:0000269|PubMed:8939961, ECO:0000269|PubMed:9360638,
FT                   ECO:0000303|PubMed:7833947"
FT                   /id="VAR_000652"
FT   VARIANT         145
FT                   /note="G -> D (found in a patient with
FT                   hypercholesterolemia; uncertain significance; ApoE1
FT                   Weisgraber; dbSNP:rs267606664)"
FT                   /evidence="ECO:0000269|PubMed:26802169,
FT                   ECO:0000269|PubMed:8287539"
FT                   /id="VAR_000653"
FT   VARIANT         145
FT                   /note="G -> GEVQAMLG (in HLPP3; ApoE3 Leiden; no effect on
FT                   glycosylation)"
FT                   /evidence="ECO:0000269|PubMed:2556398,
FT                   ECO:0000269|PubMed:8468528"
FT                   /id="VAR_000654"
FT   VARIANT         152
FT                   /note="R -> Q (in ApoE2-type; no hyperlipidemia;
FT                   dbSNP:rs28931578)"
FT                   /evidence="ECO:0000303|PubMed:7833947"
FT                   /id="VAR_000655"
FT   VARIANT         154
FT                   /note="R -> C (in HLPP3; ApoE2-type; dbSNP:rs121918393)"
FT                   /evidence="ECO:0000303|PubMed:7833947"
FT                   /id="VAR_000657"
FT   VARIANT         154
FT                   /note="R -> S (in HLPP3; ApoE2 Christchurch; decreased
FT                   binding to LDL receptor; dbSNP:rs121918393)"
FT                   /evidence="ECO:0000269|PubMed:22481068,
FT                   ECO:0000269|PubMed:2831187, ECO:0000269|PubMed:8287539"
FT                   /id="VAR_000656"
FT   VARIANT         160
FT                   /note="R -> C (in HLPP3; ApoE3**; dbSNP:rs387906567)"
FT                   /evidence="ECO:0000269|PubMed:8287539"
FT                   /id="VAR_000658"
FT   VARIANT         163
FT                   /note="R -> C (in HLPP3; also found in a patient with
FT                   hypercholesterolemia; ApoE4 Philadelphia and ApoE2-type;
FT                   dbSNP:rs769455)"
FT                   /evidence="ECO:0000269|PubMed:11042151,
FT                   ECO:0000269|PubMed:1674745, ECO:0000269|PubMed:26802169"
FT                   /id="VAR_000659"
FT   VARIANT         163
FT                   /note="R -> H (in HLPP3; uncertain significance; ApoEKochi;
FT                   dbSNP:rs121918397)"
FT                   /evidence="ECO:0000269|PubMed:2101409"
FT                   /id="VAR_000660"
FT   VARIANT         163
FT                   /note="R -> P (in LPG; ApoE2 Sendai; decreased binding to
FT                   LDL receptor; induces intraglomerular deposition of
FT                   ApoE-containing lipoproteins; dbSNP:rs121918397)"
FT                   /evidence="ECO:0000269|PubMed:10903326,
FT                   ECO:0000269|PubMed:9176854"
FT                   /id="VAR_042735"
FT   VARIANT         164
FT                   /note="K -> E (in HLPP3; ApoE1 Harrisburg; decreased
FT                   binding to LDL receptor; probable dominant negative effect;
FT                   decreased in vitro binding to heparin; dbSNP:rs121918394)"
FT                   /evidence="ECO:0000269|PubMed:7635945"
FT                   /id="VAR_000662"
FT   VARIANT         164
FT                   /note="K -> Q (in HLPP3; ApoE2**; dbSNP:rs121918394)"
FT                   /id="VAR_000661"
FT   VARIANT         167
FT                   /note="Missing (in SBHD; also found in patients with a
FT                   diagnosis of familial combined hyperlipidemia)"
FT                   /evidence="ECO:0000269|PubMed:11095479,
FT                   ECO:0000269|PubMed:16094309, ECO:0000269|PubMed:22481068,
FT                   ECO:0000269|PubMed:22949395, ECO:0000269|PubMed:24267230,
FT                   ECO:0000269|PubMed:26802169"
FT                   /id="VAR_035015"
FT   VARIANT         170
FT                   /note="A -> P (in ApoE3*; decreased binding to LDL
FT                   receptor; dbSNP:rs267606662)"
FT                   /evidence="ECO:0000269|PubMed:2831187,
FT                   ECO:0000269|PubMed:6327682"
FT                   /id="VAR_000663"
FT   VARIANT         176
FT                   /note="R -> C (in HLPP3; ApoE2, ApoE2 Fukuoka, ApoE1
FT                   Weisgraber and ApoE3**; ApoE3** is associated with HLPP3;
FT                   changed protein structure; decreased binding to LDLR and
FT                   other lipoprotein receptors; decreased in vitro binding to
FT                   heparin; no effect on distribution among plasma
FT                   lipoproteins; dbSNP:rs7412)"
FT                   /evidence="ECO:0000269|PubMed:11042151,
FT                   ECO:0000269|PubMed:12950167, ECO:0000269|PubMed:12966036,
FT                   ECO:0000269|PubMed:2280190, ECO:0000269|PubMed:3243553,
FT                   ECO:0000269|PubMed:7635945, ECO:0000269|PubMed:7994571,
FT                   ECO:0000269|PubMed:8287539, ECO:0000269|PubMed:8756331"
FT                   /id="VAR_000664"
FT   VARIANT         228..317
FT                   /note="Missing (in HLPP3; ApoE3 Washington)"
FT                   /evidence="ECO:0000269|PubMed:1361196"
FT                   /id="VAR_081136"
FT   VARIANT         242
FT                   /note="R -> Q (in ApoE2 Fukuoka; dbSNP:rs267606663)"
FT                   /evidence="ECO:0000269|PubMed:8664327"
FT                   /id="VAR_000665"
FT   VARIANT         246
FT                   /note="R -> C (in ApoE2 Dunedin; dbSNP:rs121918395)"
FT                   /evidence="ECO:0000269|PubMed:2341812"
FT                   /id="VAR_000666"
FT   VARIANT         254
FT                   /note="V -> E (in ApoE2 WG; dbSNP:rs199768005)"
FT                   /evidence="ECO:0000269|PubMed:8488843"
FT                   /id="VAR_000667"
FT   VARIANT         262..263
FT                   /note="EE -> KK (in HLPP3; ApoE7 Suita)"
FT                   /evidence="ECO:0000269|PubMed:2738044"
FT                   /id="VAR_000668"
FT   VARIANT         269
FT                   /note="R -> G (in ApoE3 HB; dbSNP:rs267606661)"
FT                   /evidence="ECO:0000269|PubMed:8488843,
FT                   ECO:0000269|PubMed:9360638"
FT                   /id="VAR_000669"
FT   VARIANT         270
FT                   /note="L -> E (in ApoE1 HE; requires 2 nucleotide
FT                   substitutions)"
FT                   /evidence="ECO:0000269|PubMed:8488843"
FT                   /id="VAR_000670"
FT   VARIANT         292
FT                   /note="R -> H (in ApoE4 PD; dbSNP:rs121918398)"
FT                   /evidence="ECO:0000269|PubMed:8488843"
FT                   /id="VAR_000671"
FT   VARIANT         314
FT                   /note="S -> R (in ApoE4 HG; dbSNP:rs28931579)"
FT                   /evidence="ECO:0000269|PubMed:8488843"
FT                   /id="VAR_000672"
FT   MUTAGEN         79
FT                   /note="R->T: Changes the plasma lipoprotein distribution of
FT                   ApoE4 to the HDL."
FT                   /evidence="ECO:0000269|PubMed:8071364"
FT   MUTAGEN         127
FT                   /note="E->A: No effect on plasma lipoprotein distribution."
FT                   /evidence="ECO:0000269|PubMed:8071364"
FT   MUTAGEN         157
FT                   /note="S->R: Increased binding to LDL receptor; when
FT                   associated with A-167."
FT                   /evidence="ECO:0000269|PubMed:2831187"
FT   MUTAGEN         158
FT                   /note="H->A: Decreased binding to LDL receptor."
FT                   /evidence="ECO:0000269|PubMed:2831187"
FT   MUTAGEN         161
FT                   /note="K->A: Decreased binding to LDL receptor."
FT                   /evidence="ECO:0000269|PubMed:2831187"
FT   MUTAGEN         162
FT                   /note="L->P: Decreased binding to LDL receptor."
FT                   /evidence="ECO:0000269|PubMed:2831187"
FT   MUTAGEN         167
FT                   /note="L->A: Increased binding to LDL receptor; when
FT                   associated with R-157."
FT                   /evidence="ECO:0000269|PubMed:2831187"
FT   MUTAGEN         168
FT                   /note="R->A: Decreased binding to LDL receptor."
FT                   /evidence="ECO:0000269|PubMed:2831187"
FT   MUTAGEN         172
FT                   /note="D->A: Restores the LDL receptor binding activity of
FT                   ApoE2."
FT                   /evidence="ECO:0000269|PubMed:8756331"
FT   MUTAGEN         212
FT                   /note="T->A: Loss of O-glycosylation."
FT                   /evidence="ECO:0000269|PubMed:2498325"
FT   STRAND          22..24
FT                   /evidence="ECO:0007829|PDB:2KC3"
FT   HELIX           31..39
FT                   /evidence="ECO:0007829|PDB:2KC3"
FT   TURN            40..42
FT                   /evidence="ECO:0007829|PDB:2KC3"
FT   HELIX           43..60
FT                   /evidence="ECO:0007829|PDB:7FCR"
FT   HELIX           63..70
FT                   /evidence="ECO:0007829|PDB:7FCR"
FT   HELIX           73..96
FT                   /evidence="ECO:0007829|PDB:7FCR"
FT   HELIX           97..99
FT                   /evidence="ECO:0007829|PDB:7FCR"
FT   STRAND          103..105
FT                   /evidence="ECO:0007829|PDB:7UVJ"
FT   HELIX           107..142
FT                   /evidence="ECO:0007829|PDB:7FCR"
FT   TURN            143..145
FT                   /evidence="ECO:0007829|PDB:7FCR"
FT   HELIX           149..180
FT                   /evidence="ECO:0007829|PDB:7FCR"
FT   TURN            187..190
FT                   /evidence="ECO:0007829|PDB:2KC3"
FT   HELIX           193..198
FT                   /evidence="ECO:0007829|PDB:2KC3"
FT   STRAND          200..202
FT                   /evidence="ECO:0007829|PDB:2L7B"
FT   HELIX           209..217
FT                   /evidence="ECO:0007829|PDB:2L7B"
FT   HELIX           228..241
FT                   /evidence="ECO:0007829|PDB:2L7B"
FT   HELIX           257..283
FT                   /evidence="ECO:0007829|PDB:2L7B"
FT   HELIX           286..303
FT                   /evidence="ECO:0007829|PDB:1OEF"
FT   STRAND          307..309
FT                   /evidence="ECO:0007829|PDB:2L7B"
SQ   SEQUENCE   317 AA;  36154 MW;  91AFC04210A30689 CRC64;
     MKVLWAALLV TFLAGCQAKV EQAVETEPEP ELRQQTEWQS GQRWELALGR FWDYLRWVQT
     LSEQVQEELL SSQVTQELRA LMDETMKELK AYKSELEEQL TPVAEETRAR LSKELQAAQA
     RLGADMEDVC GRLVQYRGEV QAMLGQSTEE LRVRLASHLR KLRKRLLRDA DDLQKRLAVY
     QAGAREGAER GLSAIRERLG PLVEQGRVRA ATVGSLAGQP LQERAQAWGE RLRARMEEMG
     SRTRDRLDEV KEQVAEVRAK LEEQAQQIRL QAEAFQARLK SWFEPLVEDM QRQWAGLVEK
     VQAAVGTSAA PVPSDNH
//
